annual reportkey figures group sales operating free cash flow million chf cer million chf cer core operating profit ifrs net income million chf cer million chf cer core earnings per share dividend chf cer chf total shareholder return value chf invested period ending dec feb apr jun aug oct dec roche gs price roche b price peer set index sustainable company patients clinical trials patients treated employees global leader innovation biotech oncology vitro diagnostics hospital markets cer constant exchange rates average fullyear prices translated constant chf exchange rates ifrs international financial reporting standards usd eur jpy gbp proposed board directors one roches top selling products fulltime equivalentsroche annual report making innovation accessiblekey events roche group roche delivered strong john c reed became head performance pharma research increase ifrs early development net income agm prior joining roche board directors ceo sanfordburnham propose increase medical research institute dividend chf california united states would th increase many years roche signed agreements roche announced plans partners across multi invest million swiss francs tude areas including immu global biologic medi notherapy cancer anti cine manufacturing biotics multiresistant network meet increasing bacteria technologies demand new diagnostic tests pharmaceuticals kadcyla became first fda granted perjeta antibodydrug conjugate accelerated approval approved united states use surgery european union people herpositive treatment people earlystage breast cancer herpositive metastatic breast cancer gazyva received us approval roche discontinued treatment people development activities previously untreated aleglitazar medicine chronic lymphocytic leukemia aimed treating diabetes related heart condition phase iii trial reviewcorporate sustainability fifth consecutive decade commitment year roche recognised since first roche chil dow jones sustainability drens walk roche indices djsi group employees worldwide gen leader sustainability within erated million pharmaceuticals biotech swiss francs support nology life sciences indus vulnerable children malawi try rest world roche medicines patent roche reached total pool signed agreement women key increase access valcyte positions year treat cmv infection ahead diversity hiv patients major cause goal blindness diagnostics roche launched cobas roche acquired constitution fully automated lab medical investor inc solution improves labo developing innovative ratorys throughput testing hematology testing sys efficiency enabling healthcare tem system designed professionals make fast provide faster reliable treatment decisions accurate diagnosis blood related diseases cobas hpv test cervical four new cancer tests cancer screening received screen diagnose breast prix galien greece cervical lung thyroid award best diagnostic cancer launched tool prix galien awards year considered equiva lent nobel prizes scientific communityhow make difference roche innovationdriven business invested billion swiss francs research development produce stateoftheart medicines diagnostic tests provide significant medical benefit topselling pharmaceuticals millions chf mabtherarituxan avastin herceptin lucentis xeloda oncology oncology oncology ophthalmology oncology immunology nonhodgkins colorectal breast herpositive wet agerelated colorectal colon lymphoma lung kidney ovarian breast cancer one macular degeneration breast cancer unlike common cancer cancer glioblas aggressive macular edema follow many chemother lymphatic system toma type brain forms breast cancer ing retinal vein occlusion apy cancer treatments chronic lymphocytic tumour works affecting around diabetic macular given leukemia one starving tumours patients diagnosed edema diseases intravenously xeloda common forms blood supply disease cause severe dam pill stops cancer blood cancer well also approved treat age eye cells growing rheumatoid arthritis herpositive gastric decreases size cancer tumour pharmaceuticals oncology immunology infectious diseases ophthalmology neuroscience sales chf billion roche new molecular entities pipeline hope one day compounds become medicines diseases currently either treatment options roche produce generic biosimilar nonprescription drugs sales growth constant exchange rates average fullyear topselling diagnostics millions chf cobas e accuchek nano cobas c benchmark ultra cobas ampliprep immunodiagnostic smartview clinical chemistry tissue diagnosis virology blood glucose meters broad portfolio meters broad portfolio advanced staining used early modular instruments designed selfmoni modular instruments tissuebased tests detection viruses software wide toring blood glucose software wide visualise identify hiv human range immunology help people range tests based molecular targets papilloma virus based tests including diabetes keep clinical chemistry cancer tissue hepatitis b c viruses tests tumours blood glucose levels including tests thy targets help identify test results help physi heart diseases control roid dysfunction cho making cians identify lesterol triglyc erides specific cancer grow optimal therapy important tests en abling doctors patient assessing health choose best therapy status example patient heart diagnostics immunoassays diabetes clinical chemistry pcr tests tissue cancer tests sales chf billion roche develops diagnostic systems tests lab customers medical practitioners patients healthcare systems divisions strategy built two pillars testing efficiency medical valuemaking innovation accessible roche works partnerships world make sure many patients possible benefit medicines diagnostic tests examples initiatives found annual report working together treat striving put healthcare helping fight newborn babies risk philippines reach hepatitis b china hiv subsaharan africa overcoming hurdles working together make helping establish private egypt improve access healthcare budgets go health insurance cancer treatment europe china supporting healthcare supporting people diabetes making sure everyone system peru treat cancer pakistan access medicines uscontents key figures letter chairman board directors key events honour dr franz b humer corporate executive committee make difference letter ceo business review group results outlook strategy market environment research development highlights accessing external innovation diagnostics conducting responsible r manufacturing procurement pharmaceuticals procurement diagnostics quality compliance markets medical value making innovation accessible customised solutions education healthcare professionals responsible business strengthening compliance managing risk crisis increasing transparency safeguarding patient safety people priorities performance leadership diversity talent attraction retention community involvement humanitarian social projects science education natural disaster support arts culture safety security health environment occupational accidents diseases water management energy management air emissions security corporate governance remuneration report corporate governance remuneration report web independent assurance report roche corporate responsibility reportingletter shareholders franz b humer dear shareholders last letter chairman gives great pleasure report excellent performance roche group challenging increasingly costsensitive environment focus targeted medicines diagnostic tests allowed us expand strong market position significantly improve net income light strong performance board directors proposing th consecutive year increase dividend roche posted strong results group sales increased todays healthcare challenges roche developing medicines constant exchange rates billion swiss francs improve prolong lives patients swiss francs overall net income grew sharply also save significant resources parts health billion swiss francs swiss francs care sector end diagnostic testing increasingly play ing criti cal role detection disease monitoring increasing demand medicines diagnostic treatment modalities development targeted tests especially five new cancer treatments launched treatments reduce overall costs healthcare last two years pipelines amongst system strongest industry results reaffirm roche strategy focusing innovation medicines diagnos one roches strengths significant biotech knowhow tics resulting competitive advantage devel expertise area opens world new possibilities oping medically differentiated products strengths treat disease bringing real medical breakthroughs pa become even important future targeted cost tients leadership biotech also result targeted effective treatments key role play overcoming acquisitions genentech merger transac roche annual report letters shareholderstion biggest impact pharmaceuticals march majority swiss citizens voted refer en business diagnostics became market leader dum favour set changes swiss constitution acquired boehringer mannheim past regarding governance regulations listed companies roche years systematic focus innovation selective decided comply new regulations earlier transactions roche become worlds leading company required propose changes companys articles oncology global number one vitro diagnostics incorporation years agm important ones focus pharmaceuticals diagnostics enable us include chairman board members succeed increasingly competitive marketplace board directors members remuneration committee elected annually share hold ers doubt mind roche unique company furthermore propose implement b ind ing votes true today two decades ago remuneration ahead mandatory date joined unique culture unique majority ownership original founding family light strong performance board allows us take longterm view pursue longterm di rec tors proposing dividend increase swiss strategy develop innovative products hoffmann francs per share nonvoting equity security oeri families sincere gratitude support swiss francs making th dividend increase many given throughout career roche years approved half net income distributed shareholders dividends selection dow jones sustainability indi ces worlds sustainable healthcare company would like thank roche shareholders trust another indication roche right track roche past years immensely enjoyed work singled distinction fifth year row board management employees roche rating recognises commitment behaving ethically proud accomplished together responsibly creating longterm value stake roche truly great company holders foundations roche rocksolid predeces sor used say house roche never finished com pany automatic right prosperity needs earned confident new generation leaders executive committee everin schwans leadership board directors continue build franz b humer chairman board successful business enrich roche culture chosen annual general meeting agm march moment step chairman roche group worked pharmaceutical industry years half roche head pharmaceuticals division ceo chairman board forthcoming agm roche board directors pro pose christoph franz served non exec utive director roches board since elected chair man board christoph franz roche chairman outstanding personal qualities impres sive record head major global company sure extensive experience exceptional worldwide network great assets letters shareholders roche annual report dr franz b humer head pharmaceuticals division member board directors roche holding ltd chief operating officer chief executive officer chief executive officer chairman board directors roche holding ltd chairman board directors roche holding ltdin honour dr franz b humer many thanks franz humer great enduring success roche achievement employees especially result farsighted strategic operational course set past years dr franz b humer dr humer retire chairman annual general meeting reason enough pay tribute exceptional career company dr humer joined roche head pharmaceuticals division member board directors year later named chief operating officer assumed overall responsibility chief executive officer characteristic persistence knowledge short saw evolu focused activities pharmaceu tion industry many ticals diagnostics businesses peers strength turn vation shortterm thinking vision reality eye next quarters results little interest actions would like warmly thank guided clearly formulated strategy franz b humer behalf board equally comprehensible em directors oeri hoffmann ployees shareholders alike families grateful dr humer experience knowledge following retirement fritz company owes lot retiring continue advise roche board gerber franz b humer elected chairman roche today un chair man board served disputed leader oncology large roles severin part due bold decisions made schwan named ceo dr humer challenging pe years knowledge strategic riod company beginning vision impressive management skills century franz b humer believed strong personality dr humer value close collaboration shaped continues shape pharmaceuticals diagnostics andr hoffmann company done areas well became common vicechairman board directorsletter shareholders severin schwan dear shareholders exceptional year innovation rochewith perjeta kadcyla brought new generations treatment patients aggressive type breast cancer also received us approval gazyva treatment patients one common types leukemia growing demand medicines diagnostics reflected strong operating results exceeded financial targets year roche continued positive growth trend past year approval united states europe years sales pharmaceuticals division rose kadcyla novel medicine represents major break total billion swiss francs strong growth patients suffering aggres oncology portfolio well actemra rheumatoid sive herpositive breast cancer first antibodydrug arthritis lucentis eye medicine diagnostics sales grew conjugate highly potent chemotherapy drug ahead global vitro diagnostics market increasing attached antibody precisely target cancer cells billion swiss francs driven strong demand c li n significantly reduces side effects systemic chemo cal laboratories core operating profit grew billion therapy swiss francs core earnings per share increased constant exchange rates swiss francs milestones eu approval sub cutaneous form herceptin reduces hospital time importantly future continue make good patients perjeta combination herceptin received prog ress product pipeline exciting milestone groundbreaking approval united states first roche annual report letters shareholderstreatment patients herpositive breast cancer time access innovative patent protected treat surgery medicines significantly improve survival ments one challenging global health issues rates women herpositive breast cancer one close heart creating truly innovative medicines diagnostic tests means little dont also working towards improving standard care reach patient aim every person needs hematology tumours extending franchise mabthera products able access benefit rituxan gayzva treatment chronic end working world healthcare author lymphocytic leukemia medicine received us approval ities governments stakeholders break record time fda granted priority review barriers accessing healthcare find breakthrough therapy designation initiatives improve access throughout report pipeline number exciting compounds new looking forward expect lowto midsingle digit molecular entities total late stage group sales growth constant exchange rates tar around twothirds latestage compounds geting core eps grow constant exchange rates ahead developed companion diagnostic demonstrating sales also expect increase dividend progress making personalised healthcare confident roches future large part nature innovation involves risk therefore setbacks culture innovation thrive ultimately innova along way disappointment discontinua tion depends talented dedicated employees tion trials aleglitazar promising medi functions countries would like thank roche cine treat diabetesrelated heart condition employees professionalism commitment passion realigned research efforts focus fields cancer immunology autoimmune disease ophthalmology infec exciting future small part due foundations tious diseases neuroscience laid chairman franz humer stepping chairman roche group years investment r billion swiss francs amongst roche leadership roche become number highest world remain firmly committed one pharmaceutical company biotechnology oncology strategy innovation focus science core diagnostics privileged worked strength deep understanding underlying molecular greatly benefited guidance personally behalf causes disease enables us find targeted solutions executive committee roche employees would rootcauses diseases biotechnology products like thank franz humer invaluable contribution account threequarters pharmaceutical sales done roche diagnostic tests discovery development drugs long expensive pro cess uncertain outcomes patent protection funda mental researchbased company patents means rewarding creation intellectual property temporary market exclusivity ensure severin schwan resources keep investing future patents chief executive officer expire new medicines accessible mankind low prices forever proud roche medicines included world health organizations essential medicines list offpatent freely available low cost core list comprises effective safe costefficient medicines believed required basic healthcare system products would exist today without robust patent system encourages invest ments innovation see develop ment truly innovative medical products part contract society letters shareholders roche annual report board directors dr franz b humer andr hoffmann dr andreas oeri representative shareholder group representative shareholder group pooled voting rights pooled voting rights prof pius baschera prof sir john irving bell paul bulcke william burns dr christoph franz dame deanne julius dr arthur levinson dr severin schwan peter r voser board directors per december prof beatrice weder di mauro roche annual report board directorsboard directors name year birth first elected board directors dr franz b humer e chairman andr hoffmann c e vicechairman dr andreas oeri e prof pius baschera e prof sir john irving bell b e paul bulcke b e william burns e dr christoph franz c e dame deanne julius b e dr arthur levinson c e dr severin schwan peter r voser c e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson board directors forthcoming annual general meeting agm march roche board directors propose christoph franz elected chairman board christoph franz nominated succeed franz b humer announced agm march would standing reelection board directors roche annual report corporate executive committee dr severin schwan daniel oday roland diggelmann dr alan hippe silvia ayyoubi dr gottlieb keller osamu nagayama dr richard scheller prof john c reed corporate executive committee per december dr stephan feldhaus dr sophie kornowskibonnet roche annual report corporate executive committeecorporate executive committee name year birth position corporate executive committee dr severin schwan ceo roche group daniel oday coo division roche pharmaceuticals roland diggelmann coo division roche diagnostics dr alan hippe chief financial officer silvia ayyoubi head group human resources dr gottlieb keller general counsel enlarged corporate executive osamu nagayama chairman ceo chugai committee dr richard scheller head genentech research early development gred prof john c reed head roche pharma research early development pred dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate executive committee perolof attinger statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey since chief compliance officer dr urs jaisli corporate executive committee john c reed appointed head pharma research early development pred april became member enlarged corporate executive committee corporate executive committee roche annual report breaking barriers roche business report making innovation accessibleaccess healthcare remains global challenge healthcare varies dramatically country country countries sophisticated medicines tests widely available whilst others little basic infrastructure even established markets medicines take years become available patients roche works partnerships world try make difference help break barriers healthcare run programmes tailored specific local needs whether support disease education bring screening remote areas make products affordable examples initiatives found annual report making innovation accessible roche annual report making innovation accessible working together make healthcare budgets go europe making sure everyone access medicines us supporting healthcare system peru treat cancer roche annual report making innovation accessible helping establish private health insurance cancer china helping fight supporting people hepatitis b diabetes china pakistan overcoming hurdles egypt improve access treatment striving put healthcare philippines reach working together treat newborn babies risk hiv subsaharan africa making innovation accessible roche annual report working together treat newborn babies risk hiv roche business report making innovation accessiblesubsaharan africa africa mothertochild transmission main cause hiv children without treatment third children hiv die age one almost age two early infant diagnosis number tests conducted per year innovative testing technology expands access care remote areas early hiv diagnosis means babies get right treatment stay healthy end roche supported intro duction new way testing blood samples dried card still able effectively tested hiv results process stateoftheart procedure doctors notified test results immediately collection card expanded access hiv diagnosis throughout remot est areas southern africa roche continuing work number organisations public private partner ships ensure subsequent medical care babies hiv making innovation accessible roche annual report swiss francs core earnings per share roche annual report business review exceeded financial targets delivered strong sales growth oncology immunology ophthalmology improved cash flow reduced net debt roche annual report business review key figures group sales million chf cer core operating profit million chf cer ifrs net income million chf cer millions chf changes sales cer chf group sales pharmaceuticals division diagnostics division core operating profit pharmaceuticals division diagnostics division operating free cash flow core earnings per share chf group results outlook roche group posted strong overall results swiss franc rose number currencies exceeding financial targets year group sales mainly japanese yen us dollar leading negative increased billion swiss francs reflecting positive impact results reported swiss francs demand oncology products especially cancer products avastin well instruments tests professional diagnostics business pharmaceuticals strong sales growth sales increased diagnostics sales grew united states emerging markets main regional growth oncology immunology drivers europe performing well challenging market ophthalmology products conditions groups core operating profit grew billion swiss francs core earnings per share eps increased sales pharmaceuticals division increased constant exchange rates swiss francs billion swiss francs due strong demand prod ucts within breast cancer franchise cancer medi cines avastin mabtherarituxan actemraroactemra rheumatoid arthritis eye medicine lucentis per unless otherwise stated growth rates calculated using cer formance key growth products compensated constant exchange rates average fullyear ifrs international financial reporting standards pricing competitive pressure mature products roche annual report business reviewpegasys strong sales performance led increase actemraroactemra grew reach sales core operating profit billion swiss francs billion swiss francs first time pharmaceuticals sales products billion chf main regional sales growth drivers united states key emerging markets united states posted sales growth share rise sales sales increased key emerging vs chfm cer markets demand particularly strong china mabtherarituxan brazil europe sales rose despite ongoing avastin pricing pressure strong sales avastin japan herceptin sales higher spite termination comar lucentis keting agreement evista osteoporosis medicine exclud xeloda ing impact sales growth japan tarceva pegasys actemraroactemra pharmaceuticals sales region cer products total p harmaceuticals united states europe cancer medicines account majority pharmaceutical japan sales almost third products treat international herpositive breast cancer sales franchise consists herceptin newly launched medi cines perjeta kadcyla grew due good uptake perjeta kadcyla well growing use herceptin key emerging markets china brazil new pharmaceutical products strengthened outlook hematology avastin used treat several different types cancer product franchises important launches perjeta important growth driver sales rising kadcyla herpositive breast cancer us launch largely due strong sales treatment ovarian cancer gazyva chronic lymphocytic leukemia cll one europe increased use colorectal cancer europe common types blood cancer united states blood cancer rheumatoid arthritis med icine mabtherarituxan made significant contribution perjeta gained european approval advanced herpositive growth increase sales breast cancer march well us approval treat positive breast cancer surgery september perjeta addition oncology products pharmaceuticals division combination herceptin approved pre supported sales eye medicine lucentis surgical neoadjuvant breast cancer treatment united grew sales rheumatoid arthritis drug states also secured regulatory backing kadcyla united states europe japan making first antibodydrug conjugate adc approved treat advanced pharmaceuticals sales therapeutic area cer herpositive breast cancer adc targeted cancer medicine attach certain types cancer cells oncology deliver chemotherapy directly resulting highly potent treatment also fewer adverse side effects immunology addition received european approval subcu infectious diseases taneous formulation herceptin new formulation help significantly reduce administration time related ophthalmology neuroscience therapeutic areas roches seven key emerging markets e brazil china india mexico russia south korea turkey business review roche annual report treatment costs associated traditional intravenous diagnostics sales business area cer method administration professional diagnostics gazyva approved united states november diabetes care fda granted breakthrough therapy designation result strength data latestage trial molecular diagnostics serious lifethreatening nature cll latestage trials tissue diagnostics investigating gazyva nonhodgkins lymphoma common cancer lymphatic system well diffuse large bcell lymphoma ongoing roche spent billion swiss francs pharmaceutical regions contributed growth asiapacific latin research development areas oncology immu america growing doubledigit rates sales rose nology infectious diseases ophthalmology neuroscience asiapacific china latin america pharmaceutical pipeline made significant pro europe middle east africa emea region ac gress oncology areas ophthalmology counts almost half divisions business grew immunology pipeline currently new molecular enti north america sales increased strong sales growth ties clinical development latestage de professional diagnostics business offset sales velopment based promising midstage data selected declines diabetes care japan sales grew eight nmes latestage development six com pounds oncology one immunology one compound ophthalmology diagnostics sales region cer europe middle east africa emea good growth instruments north america tests clinical asiapacific laboratories latin america japan diagnostics division grew ahead global vitro diagnostics market sales increasing billion swiss francs growth mainly driven sales profes new diagnostic products sional diagnostics business area strengthened diagnostics division spent billion swiss francs divisions position market leader core operating profit research development diagnostic instruments diagnostics division rose billion swiss francs tests roche launched major products including instru divisions core operating profit margin remained stable ments advance lab automation new devices diabetes management well additions test menus professional diagnostics divisions largest business area existing instruments one key introductions benefited strong growth immunoassay business cobas preand postanalytics instrument new sales blood glucose monitoring products decreased fully automated workflow series automates routine labora result reimbursement cuts key markets including tory tasks increases costefficiency lab reduces united states result diabetes care business unit manual handling samples continued implement restructuring measures ensure long term profitability molecular diagnostics business area grew nextgeneration blood glucose meters accuchek active growth underlying business main accuchek avivaperforma launched several markets tained position market leader strong growth accuchek aviva expert system received regulatory blood screening business tests human papilloma clearance united states virus hpv sales tissue diagnostics especially advanced staining products rose roche annual report business reviewmolecular diagnostics received label expansion tests ence business areas portfolio products integrated sexually transmitted diseases ctng us market business areas within diagnostics obtained market clearance europe several microbiology tests mrsa mssa hsv part broader initiative expand production capabilities biologic medicines actemraroactemra kadcyla late roche also obtained market clearance europe perjeta roche recommissioned discontinued produc fully automated cellbased cintec plus cytology test tion unit california resulted reversal previously used cervical cancer screening cobas hpv test incurred impairment charges also contributed ifrs screening cintec p histology test cintec plus net income cytology test roche complete cervical cer screening diagnosis product portfolio iden improved net debt position tify cervical cancer early identify cases groups operating free cash flow grew constant missed pap smear screening alone exchange rates swiss francs billion swiss francs result cash flow generated divisions despite increase inventories related new product launches positive free cash flow enabled roche improved profitability improve groups net debt position roche paid cash flow record dividend payment shareholders billion swiss francs operating profit improved core eps rose end december debt taken finance ahead sales genentech transaction repaid net groups core operating profit increased constant debt position group yearend billion exchange rates swiss francs driven strong swiss francs decrease billion swiss francs year sales performance end december net debttoasset ratio marketing distribution costs rose support growth key markets united states china patient access programmes new product launches research outlook devel opment costs increased billion swiss francs due expenses oncology neuroscience disease areas including trials recently launched products well roche expects low midsingle digit group sales pipeline products growth constant exchange rates core eps targeted grow cer ahead sales roche expects roches core earnings per share eps excludes non increase dividend core items global restructuring charges amorti sation impairment goodwill intangible assets rose swiss francs per share driven strong operating performance lower financing costs debt incurred finance genentech transaction net income growing strongly ifrs net income rose billion swiss francs swiss francs due good operating performance lower financing costs significantly lower global restructuring expenses roche completed operational closure us nutley site schedule end restructuring measures improve efficiency profitability diabetes care business area also underway former applied sci business review roche annual report market environment ageing populations rising healthcare costs growing economic access healthcare pressures new opportunities emerging markets driv parts developing world lack resources infra ing rapid change healthcare market meanwhile new structure education means many people scientific discoveries technologies providing unprece even basic healthcare healthcare spending per capita varies dented insight disease mechanisms drawing significantly countries even within countries scientific insights expertise pharmaceuticals diag also significantly influence access healthcare nostics roche responding market challenges devel oping innovative products prevent diagnose treat access healthcare related cost become disease important issue united states implementation major provisions patient protection affordable care act continues developed countries governments facing budget pressures challenged assumption healthcare systems universal access new medicines reflected pressure reimbursement approvals healthcare systems face many challenges populations across access healthcare remains global challenge world growing older patients expecting healthcare providers many people leading un healthy lifestyles treatment patients suffering number medical issues becoming complex thus costs rising time budgets tightening effec tive allocation limited resources vital healthcare sys tems particularly longterm market trends suggest many challenges likely intensify unmet medical need twothirds diseases either still treated adequately treated expected agerelated illnesses usd usd cancer alzheimers disease cardiovascular prob usd usd lems increasingly major challenges healthcare usd systems effective diagnoses medicines essential data reducing overall burden disease society total private public per capita expenditure healthcare usd average exchange rates source value money response governments trying adapt healthcare systems tackle healthcare needs well keep costs control payers playing central role deter mining whether medicine make doctors patients using stringent criteria deciding whether give product necessary financial support health tech nology assessments assessments medical social ethi cal economic implications new medicines tests becoming increasingly important healthcare providers try determine treatments available patients cost roche annual report business reviewour markets role healthcare industry roche sales pharmaceutical products pharma ceutical market usd billion estimated grow annually growth expected come innovation emerging markets mature global pharmaceutical diagnostics industries con markets north america europe japan expected tributing efficient effective healthcare solutions grow period major spending medicines accounts onetenth product area oncology expected grow annually total healthcare bill developed countries worldwide next five years risen slower pace overall spending healthcare recent years pharmaceutical market sales usd billion spending healthcare medicines cagr total healthcare expenditure per capita index north america europe japan row source ims health prognosis sep roche analysis compound annual growth rate total healthcare expenditure per capita index total medicines expenditure per capita index roche sales diagnostic instruments tests source ims health prognosis sep roche analysis vitro diagnostics market valued estimated usd billion sales market expected grow coming five years developed markets innovative medicines enable diseases treated faster emerging markets important growth effectively lower cost newer treatments reduce drivers expanding within number patients treated hospitals reduce length diagnostics market professional diagnostics market hospital stay moreover diagnostic testing enables faster expected grow overall market rate blood accurate diagnosis disease leading lower costs glucose monitoring expected grow less delay ultimately better medical outcomes diagnostic testing currently accounts less healthcare spending yet medical decisions depend diagnostics market sales usd billion vitro diagnostic tests cagr north america europe japan row source roche estimates validated independent ivd consultancy compound annual growth rate business review roche annual report strategy leader oncology treatment fur ther improved standard care herpositive breast cancer launches kadcyla perjeta working towards improving standard care hematol roche strive make difference lives millions ogy moving mabtherarituxan developing new medi patients around world medicines vitro cines like gazyva diagnostic tests believe products provide significant medical benefits patients doctors also building strength biotechnology efficiency gains laboratories health economic benefits believe enormous potential modern biological payers sciences understanding underlying mechanisms grows ability develop targeted treatments focusing patient make important contribution managing chal put patient centre business model lenges currently confronting healthcare systems strengths million people received treatment one top biotechnology research development manufacturing products million people treated roche prod mean ideally equipped translate insights cell ucts offpatent essen biology new treatments tests tial drug list patients received access inno vative treatments clinical trials programmes roche worlds biggest biotechnology company current products improve prolong lives important biopharmaceutical medicines market investiga disease areas cancer arthritis hepatitis diabetes tional biopharmaceuticals pipeline seven ten top selling medicines biopharmaceuticals leading setting new standards care diagnostics company diagnostic tests currently invest almost billion swiss francs research supply also based biotechnology plan vigorously development every year create medically differentiated continue research investments area products pursuit excellence science research announced major investment million swiss francs focused areas oncology immunology ophthalmol biotech production capacity ogy infectious diseases neuroscience innovation internal hubs worldwide network gives research activities breadth external networks diversity flexibility roche pioneer partnering third pipeline third marketed products origi nate external partnerships roche one first pharmaceutical companies develop global network dedicated specialised research centres operating high degree autonomy ensure diversity scientific approaches combine critical mass large research company flexibility smaller research units roche groups four independent research organisations pharma research early development genentech research early development chugai japan diagnostics division form hubs internal innovation network complement strong inhouse capabilities ex tensive network external partnerships partners roche annual report business reviewdriving personalised healthcare making innovation accessible personalised healthcare phc providing right despite remarkable breakthroughs diagnosing treating therapy right group patients right time phc disease ensuring patients access break enormous potential combating cancer dis throughs remains significant challenge main contribu eases effectively drawing insights patients tion challenge deliver innovation developing genetic biological differences medicines medicines diagnostics prolong improve peoples increasingly tailored specific patient populations lives however also work many different partners populations identified modern diagnostic tests reduce barriers prevent people diagnosed combined strength pharmaceuticals diagnos treated products healthcare systems tics proven expertise molecular biology better around world different complex equipped company drive personal single global approach provide tailored solutions ised healthcare allowing doctors pinpoint patients address needs individual country including inno likely benefit drug thus enabling healthcare vative pricing models personalised reimbursement models systems allocate resources effectively patient access programmes health infrastructure health education programmes aim every person needs roche one first companies bring targeted treat products able access benefit ments patients launch herceptin recently zelboraf perjeta kadcyla heart approach use biomarkers predict therapy outcomes clinic also refine process developing drugs diagnostics twothirds latestage compounds developed com panion diagnostic addressing healthcare challenges healthcare challenge roche strategic response unmet medical need existing products cancer arthritis hepatitis diabetes improve patient care future targeted treatments cancer immunology infectious deseases ophthalmology neuroscience value money truly innovative medicines diagnostic tests demonstrable medical economic benefits personalised healthcare target treatments optimise patient care access healthcare innovative pricing models patient access programmes partner public private healthcare providers improve access products business review roche annual report striving put healthcare reach roche business report making innovation accessiblephilippines increasing access roches breast cancer medicine herceptin reduced price working make sure medicines affordable philippines public healthcare system cover cost medicines patients often pay pocket treatment especially sophisticated medicines majority unaf fordable address problem roche philippines developed socialised pricing programme considers individual affordability level patient doctor prescribes one cancer medicines external agency makes financial assessment discount pre scribed medicine may granted based patients capacity pay making innovation accessible roche annual report collaborations pharmaceuticals diagnostics roche annual report research development launched three new medicines fight breast blood cancer explored new ways using immune system tackle cancer entered key partnership take drugresistant bacterial infection roche annual report research development key figures core research development expenditure roche group million chf cer sales pharmaceuticals million chf cer sales diagnostics million chf cer sales cer constant exchange rates average fullyear highlights pharmaceuticals milestone compound indication approvals us gazyva previously untreated chronic lymphocytic leukemia kadcyla herpositive metastatic breast cancer perjeta herpositive breast cancer neoadjuvant approvals eu herceptin subcutaneous herpositive breast cancer kadcyla herpositive metastatic breast cancer second later lines perjeta herpositive metastatic breast cancer first line key phase iii trial results avastin advanced cervical cancer gog avastin newly diagnosed glioblastoma multiforme avaglio gazyva chronic lymphocytic leukemia cll kadcyla herpositive metastatic breast cancer thresa diagnostics major product launches cobas accuchek active capctm hcv test key clinical study results prognosis preeclampsia test interim results abacus study diabetes approval obinutuzumab ga trade name gazyva granted united states time publication harnessing diversity research early development carried maximise r activities genentech research early development gred roche pharma research early development pred activities supported chugai japanese year invest heavily researching developing subsidiary well external partners currently new medicines diagnostic tests focus oncology alliances companies institutes immunology ophthalmology infectious diseases neuro outside company compounds successfully developed science draw expertise within outside gred pred chugai partners go global late company maximise output ensure invest stage development unit ment yields sustainable results roche annual report research developmentwe strive excellence science basis deep also accelerated approval perjeta united understanding underlying biology behind diseases states treatment herpositive breast cancer prior end built extensive expertise molecular surgery neoadjuvant perjeta combined cellular biology past decades truly medicine herceptin chemotherapy first approved standing cells behave replicate interact treat advanced herpositive breast cancer able modulate biochemical pathways speed approval perjeta neoadjuvant setting give cells information energy need grow exceptional often take several years medicine knowledge understanding vital part devel secure backing earlier use initial approval opment new medicines number diseases including l aterstage indication cancer perjeta granted approval phase ii neosphere entire process drug development underpinned trial showed nearly people receiving perjeta herceptin diagnostics division plays invaluable role chemotherapy evidence tumour time developing companion diagnostics tests mean surgery known pathological complete response pinpoint patients likely respond medicines pcr perjeta approved neoadjuvant breast early development process allow us design cer treatment united states also first effective efficient trials well better safer medi approved based pcr data cines approach crucial personalised healthcare strategy currently investigating combination perjeta kadcyla treat advanced herpositive breast cancer currently potential new medicines pipeline expect results phase iii marianne trial read potential diagnostic instruments tests devel second half opment around twothirds latestage compounds developed companion diagnostic hematology franchise boosted us launch gazyva chronic lymphocytic leukemia cll one recognised one innovative common forms blood cancer phase iii headtohead companies worldwide thomson reuters genentech study cll demonstrated clear efficacy benefit gazyva corporate award economists innovation awards mabtherarituxan also reported encouraging data oral smallmolecule bcl inhibitor rg latestage development rg bcl inhibitor planned start early cll phase ii trials nonhodgkins lym phoma due begin first half pharmaceuticals made significant progress antipdl antibody strengthened herpositive breast rg new type cancer treatment designed restore cancer franchise well hematology portfolio three patients immune system able fight tumour innovative products areas cells molecule moved latestage development nonsmall cell lung cancer promising phase efficacy data launch kadcyla united states europe presented rg developed advanced herpositive breast cancer particularly aggres investigational companion diagnostic could also sive form disease affecting around people used treat cancer types alone com bi breast cancer brought revolutionary new treatment option nation existing cancer medicines physicians patients avastin zelboraf kadcyla antibodydrug conjugate adc first decided stop development aleglitazar regular kind approved treat type breast cancer safety review alecardio phase iii trial investigating adc targeted cancer medicine attach certain compound type diabetes detected safety signals lack types cancer cells deliver chemotherapy directly resulting highly potent medicine also fewer adverse side effects rg listed gdcabt clinicaltrialsgov rg listed mpdla clinicaltrialsgov research development roche annual report efficacy means longer compounds newly diagnosed slowgrowing nhl gallium third cardiovascular disease latestage pipeline assets latestage study evaluating gazyva combination ben early development evaluated damustine type chemotherapy versus bendamustine alone treat patients nhl responded previous treatment gadolin goya trial expected read results gallium gadolin oncology studies due worlds leading provider cancer drugs roche gazyva first type ii anticd medicine glyco developed medicines treat number different cancers engineered means specific sugar molecules cancers breast skin colon ovaries lung modified drug change way interacts hope development new medicines area bodys immune cells gazyva attacks targeted cells help patients live longer better lives directly together bodys immune system stepping fight blood cancer also investigating gazyva combination rg around half blood cancers occur year gdc bcl inhibitor bcl protein highly lymphomas cancers lymphatic system lymphatic expressed cll indolent nhl aggressive lym system made lymph nodes neck armpits groin phomas variety solid tumours bcl inhibitor chest abdomen part immune system lympho developing abbvie designed promote mas caused abnormal growth lymphocytes type apoptosis latestage development rg planned white blood cell start beginning phase data showed overall response rate patients nhl either nhl common cancer lymphatic system returned initial treatment relapsed failed cll common type leukemia western respond given treatment refractory data also showed world causing around deaths worldwide year overall response rate patients relapsed refractory cll nhl cll bcell malignancies high levels protein called cd found surface malignant pipeline potential hematology medicines also includes bcells protein mabtherarituxan antibodydrug conjugate adc polatuzumab vedotin newest blood cancer medicine gazyva obinutuzumab anticdb phase ii trial currently evaluating com designed target pound combination mabtherarituxan launched mabtherarituxan currently standard using immune system fight cancer care nhl cll used treat nearly mil immunotherapy new approach fighting cancer lion cancer patients hope able works overcoming certain mechanisms interfere improve mabtherarituxan gazyva bcl bodys ability destroy tumour cells type treat inhibitor rg ment could result longterm durable responses could transform way treat cancer smart combinations far data gazyva encouraging results targeted medicines could help us support phase iii cll trial showed gazyva combination immune response fight cancer success field chlorambucil type chemotherapy helped people may even result cancer cures cancer becoming previously untreated cll live nearly year longer without chronic disease disease worsening treated mabtherarituxan type chemotherapy studies investigat antipdl antibody rg moved latestage ing dose safety gazyva different chemotherapy development nonsmall cell lung cancer promising regimens cll ongoing phase data showed efficacy durability response patients stopped responding therapies two headtohead phase iii studies comparing gazyva mabtherarituxan currently conducted investigating gazyva combination chemotherapy firstline treatment diffuse large bcell lymphoma goya roche annual report research developmentcombining therapies pdl molecule either avastin zelboraf number optimal responses different types cancer also considering using gazyva bcl inhibitor treat certain types blood cancer combination different cancer therapies likely play key role way tackle cancer moment evidence one drug blocks particular disease pathway limited period time cancer cells find new pathways allow continue growing aiming cut many lifelines possible cancer cells using number different medicines combat disease hope approach reduce resistance increase length time patients respond treatment exploring approach investigating combination tarceva onartuzumab lung cancer zelboraf mekinhibitor cobimetinib skin cancer well anti immunotherapy currently nine adcs clinical development eleven different types cancer encouraging earlystage clinical data cancer cell immune cell presented rg antinapib rg anti steap seen promising phase results rg antimuc patients advanced muc expressing platinumresistant ovarian cancer rg evaluated patients advanced non squamous nonsmall cell lung cancer ovarian cancer resistant platinumbased chemotherapy rg investi gated patients advanced castration resistant prostate cancer prostate cancer responded medical castration certain kinds immunotherapies designed help activate antibodydrug conjugates immune system blocking stop sign prevents immune cells destroying cancer cells antibodydrug conjugates combine boosting power antibodies antibody chemotherapy deliver medicine directly cancer cells continuing development antibodydrug conjugates adc following successful launch kadcyla adcs allow targeted delivery chemotherapy cancer cells chemotherapy linked antibody result increased efficiency fewer side effects traditionally associated chemotherapy hair loss nausea infection rg listed dniba clinicaltrialsgov rg listed dstps clinicaltrialsgov rg listed dmuca clinicaltrialsgov research development roche annual report tackling womens also developing avastin treat advanced cervical health issues cer approved avastin would used treat recurrent persistent disease accounts cases treatment advances cervical cancer roche investing medicines diagnostic tests years latestage data presented american help significantly improve health women society clinical oncology showed avastin plus chemo demand breast cancer medicines robust therapy improves median overall survival nearly four months recently launched avastin europe latin america asia months treat advanced ovarian cancer disease currently treatment options available diagnostics division also present key data pre eclampsia test test designed make easier working potential tests treatment cervi doctors predict women greatest risk develop cal cancer third common type cancer women ing serious complication pregnancy preeclampsia occurs approximately women die illness year one pregnancies lifethreatening around cases occur developing countries mother baby especially diagnosed almost cervical cancer cases caused human papilloma virus could effectively prevented better screening vaccination caught early stages cervical cancer treated successfully diagnostics division building success recently launched hpv test improve screening cervical cancer cintec plus cytology test designed detect early changes cells cervix women treated cancer develops cobas hpv test cintec histology test cintec plus cytology test roche complete cervical cancer screening diagnosis portfolio help women healthcare professionals tackle cervical cancer avoid cases could missed screening pap smear alone also developing antibodytargeted cytolytic fusion pro resistant existing treatment also able penetrate teins cfps complement adcs contrast adcs brain unlike therapies important kill proliferating tumour cells proteins could many patients advanced lung cancer die also destroy cells dividing could mean cancer spread brain alectinib moving even tumours resistant standard antiprolifer latestage development granted breakthrough ative agents could one day treated therapy designation fda encourag ing efficacy early studies patients whose cancers possible new treatment lung cancer alkpositive developing compound com alk inhibitor alectinib smallmolecule compound panion diagnostic chugai developing patients anaplas tic lymphoma kinase alkpositive nonsmall cell lung cancer nsclc accounts approximately nsclc cases drug could deliver significant benefit patients alkpositive lung cancer active tumours roche annual report research developmentimmunology affect children teenagers early age onset means costs patient healthcare systems society using understanding biology characterise patient high prevalence higher industrialised countries subgroups diseases believed homo ever also emerging asiapacific region possibly geneous hoping develop several new medicines westernisation diet ibd associated range diseases including severe asthma inflammatory significant morbidity including surgical interventions hospital bowel disease isations increased risk colon cancer working provide relief severe asthma developing etrolizumab treat crohns disease million people suffer asthma worldwide ulcerative colitis symptoms crohns disease die asthma year highest prevalence affect part gastrointestinal tract include significant europe united states australia affect abdominal pain diarrhea weight loss lack energy population mild moderate forms go undetected extended period time symptoms disease treated adequately current medications often vague cases people become mal around million people united states euro nourished body longer able absorb key pean union suffer severe uncontrolled asthma nutrients clinical presentation ulcerative colitis asthmatics burden disease extensively limit affects colon acute symptoms include fre quality life due frequent shortness breath poor exer quent bloody diarrhea abdominal pain lack energy cise tolerance asthma attacks side effects systemic crohns disease ulcerative colitis increase patients steroid treatments risk development colon cancer time currently developing lebrikizumab new treatment current treatment options modestly effective patients severe uncontrolled asthma lebrikizumab come significant side effects etrolizumab gutselec latestage trials novel humanised monoclonal antibody tive antibody beta integrin uniquely binds designed target function interleukin cytokine alphabeta alphaebeta gut selectivity dual increased patients asthma thought mode action could result important safety efficacy causal mechanism airway inflammation advantages agents integrins play important role migration cells interact en inhaled steroids current cornerstone therapy vironment etrolizumab programme evaluating alphae people uncontrolled asthma everyone responds expression gut potential diagnostic biomarker high doses inhaled steroids second controller etrolizumab moving latestage development longacting beta agonist patients could benefit lebrikizumab ophthalmology key part lebrikizumab development programme use companion diagnostic test identify people likely benefit medicine difficult mea sure building ophthalmology portfolio potential interleukin lung blood therefore necessary new treatment agerelated macular degeneration amd find surrogate interleukindriven inflammation seek develop medicines help prevent blind lung researchers identified serum periostin suitable sur ness rogate based phase ii trials periostin appears iden tify patients likely benefit lebrikizumab meeting unmet medical need amd disease associated ageing gradually results phase iii trials started expected destroy sharp central vision central vision needed see global filings planned year objects clearly common daily tasks reading driving amd leading cause blindness adults new treatment inflammatory bowel disease years age developed world two forms inflammatory bowel disease ibd chronic disease latestage amd neovascular wet amd geographic gastrointestinal tract commonly presents either crohns atrophy ga ga characterised irreversible loss disease ulcerative colitis ibd affects people primarily retinal tissue macula resulting permanent blind spots tween ages years onwards also patients central vision research development roche annual report geographic atrophy progression patients perspective resistant infections responsible usd billion excess healthcare costs usd billion societal costs usd mil lion additional hospital days news news news entered partnership deal swissbased polyphor develop pol new class antibiotic de signed treat severe hospitalacquired bacterial infections estimated ga currently affects million caused pseudomonas aeruginosa pseudomonas aeruginosa people worldwide ga become increasingly prevalent accounts one every ten hospitalacquired infections population ages us united states listed one six dangerous population aged years older may affected drugresistant microbes pol phase ii stud condition currently approved treatments ies kills pseudomonas aeruginosa novel mode action people illness overcoming resistance seen antibiotics fore potential offer new treatment options num researchers developing lampalizumab treat ga ber serious lifethreatening infections mahalo phase ii study lampalizumab showed reduction rate ga area expansion baseline month pseudomonas aeruginosa causes urinary tract infections res patient population treated monthly relative control piratory system infections dermatitis softtissue infections meeting primary endpoint trial subpopulation gastrointestinal infections variety systemic infections ga patients identified using exploratory biomarkers monthly pseudomonas infection serious problem patients lampalizumab treatment demonstrated reduction ga weakened immune system cancer area expansion relative control first study show aids severe burns patients suffering chronic positive treatment effect complement inhibitor ga diseases like cystic fibrosis fatality rate patient groups almost infectious diseases high rate multidrug resistant pseudonomas strengthening infectious diseases portfolio already includes molecules illnesses hepatitis b c influenza development mericitabine danoprevir hepatitis c continuing decided develop commercialise danoprevir china ascletis hope partnership help us address serious public health problem providing chinese patients data new treatment option hepatitis c new ways treat bacterial infections one area particular interest development medicines could one day fight infections becoming resistant existing antibiotics resistance antibiotics serious growing problem treatment infectious diseases pathogens longer antibiotic options anti carabapenemresistant p aeruginosa microbial resistancerelated deaths occur european union every year costing european economy b illion euros annually united states antibiotic httpwwwcdcgovmediareleases efpia review fantimicrobialresistancehtml roche annual report research developmentour scientists also exploring use antibodybased gressive ms trials fully recruited antici therapies attach antibiotics antibodies antibiotics pate phase iii data delivered directly sites infection first investi gational therapy using concept expected enter tackling alzheimers disease clinic late looking new mechanisms treat gantenerumab developed treat patients pro antibioticresistant staphylococcus aureus gram dromal mild alzheimers disease showing signs positive gramnegative pathogens show increasing mild cognitive impairment evidence amyloid resistance currently available antibiotics plaques brain goal early treatment slow progression disease prevent damage brain phase iii scarlet road trial ongoing development diagnostic test helping us identify neuroscience patients likely respond gantenerumab expect first results trial understanding brain works signif icantly improved last decade working also working crenezumab alzheimers number compounds could mark shift way would used patients mild moderate alzheimers diseases like schizophrenia multiple sclerosis ms alzheim antibody targets solid particles beta amyloid ers disease neurodevelopmental disorders treated make plaques brain freefloating soluble future forms abeta protein crenezumab phase ii develop ment also investigated api prevention trial taking schizophrenia known colombian study study led banner schizophrenia serious public health problem affecting ap alzheimers institute collaboration national insti proximately worlds population leading cause tutes health disability schizophrenia characterised three broad cat egories symptoms negative symptoms include social addition gantenerumab crenezumab two antiabeta withdrawal lack motivation positive symptoms antibodies developing monoamine oxidase inhibitor hallucinations delusions cognitive deficits maob alzheimers maob small molecule cur involve memory problems difficulty concentrating rently phase ii development maob inhibitor aims schizophrenia molecule bitopertin firstinclass oral improve cognitive function behavioural problems glycine reuptake inhibitor designed improve nmethyld alzheimer patients mild moderate dementia stage aspartate nmda receptor function thought diminished people schizophrenia clinical researching treatment options trial programme bitopertin called searchlyte comprised neurodevelopmental disorders six phase iii studies three suboptimally controlled symp also one pharmaceutical companies com toms three negative symptoms announced mitted finding new treatment options individuals january two phase iii studies bitopertin adults neurodevelopmental disorders autism fragile x persistent predominant negative symptoms schizo downs syndrome currently three compounds phrenia meet primary endpoints remaining clinical trials va rg autism mglu rg four studies ongoing expect data later fragile x phase ii development gabaa rg downs syndrome phase trials potential new medicine multiple sclerosis ocrelizumab latestage development ms debil itating neurological illness ocrelizumab firstinclass humanised monoclonal antibody designed selectively target cdpositive bcells thought play important role ms results phase ii trial relapsing remitting ms showed ocrelizumab significantly reduced disease activity measured brain lesions relapse rates phase iii clinical programme consists two studies patients relapsing ms one study patients primary pro research development roche annual report diagnostics key companion diagnostics projects diagnostics division developing number instruments compound disease biomarker solutions improve medical outcomes make testing alectinib alkpositive alk efficient strive strengthen position nonsmall cell lung worlds leading supplier vitro diagnostics ivds ivds cancer play key role helping doctors detect diagnose dis antipdl solid tumours pdl eases select appropriate treatments monitor patient rg sponse care tests either performed labora gantenerumab alzheimers isease amyloid beta tory point care blood tissue patient lampalizumab geographic trophy complement samples factor cfi lebrikizumab asthma periostin providing medical value mek inhibitor solid tumours braf kras offering tests enable patients physicians obtain rg nras mutations medically relevant information able improve onartuzumab lung cancer met expression comes patients one area recently made metmab lot progress development tests help doctors treat patients suffering heart disease effectively improving lab efficiency patient safety heart failure often result reduced quality life frequent laboratories increasing pressure generate reli able hospitalisation complex treatment approaches high costs results faster ever time resources high mortality recent clinical trials shown becoming scarce management heart failure improved help elecsys ntprobnp test measures level developing fully automated instruments like cobas ntprobnp blood people suffering heart failure help laboratories become efficient processing measuring biomarker doctors determine best ever increasing amounts information cobas pro course treatment individual patients guideit study vides short predictable turnaround times blood samples example collaboration industry academia helping physicians make fast treatment decisions patients national institutes health united states urgent cases prioritised processed designed show ntprobnp used guide heart twice speed earlier version system impor failure treatments believed maintaining ntprobnp tantly automation much process significantly certain level healthcare professionals improve improves patient safety reducing risk sample mixups quality life lower mortality rates heart failure patients contamination occur manual handling trial end cobas launched highsensitive troponin test designed improve also developing cobas cobas comes people suspected risk heart laboratories high demand blood screening attack thanks high sensitivity test patients virology tests cobas designed process ischemic symptoms risk future cardiac events samples diagnosis eighthour shift cobas identified earlier clinical study shown handle samples time period test improved earlier diagnosis heart attack systems could allow laboratories consolidate assays onto single platform improving workflow efficiency field molecular diagnostics also opening number aiming launch instruments new treatment options range diseases molecular analysis human dna confirm presence disease also working new programmes cobas genes detect altered genes proteins disturbing infinity solution help laboratories boost output normal cell function together genetic profile new solution launched end patient also predict whether person respond well gives customers flexibility need thanks fully specific treatment already seen value webbased modular functionality tests certain types cancer pipeline rich drugs developed companion diagnostic roche annual report research developmentaccessing external breakdown types partnering deals innovation product transactions research technology put great importance accessing external innovation collaborations key part r strategy roche product outlicensing partnering focuses strengthening portfolio external innovation ensuring partner choice biotechnology companies research institutes world wide nearly million science engineering researchers partnerships already resulted development lead worldwide innovative drugs come labs ing drugs like zelboraf skin cancer mabtherarituxan academia small biotech companies therefore vital certain types blood cancer rheumatoid arthritis tamiflu future continue tap ideas influenza xolair asthma actemraroactemra generated outside roche long history successful rheumatoid arthritis roche partnering signed new agreements includ analysis new drugs approved us fda ing eight product transactions research technology source kneller r nature reviews drug discovery nov importance new companies drug discovery collaborations product outlicensing agreements main key transactions january genentech afraxis enter global licensing agreement develop compounds undisclosed novel target february genentech rqx enter drug discovery collaboration discovery development novel drug compounds undisclosed target april roche ascletis enter collaboration advance treatment options chinese patients hepatitis c may roche california institute quantitative biosciences qb partner identify fund support earlystage life science startup companies san francisco bay area june genentech immunocore enter collaboration discovery development multiple novel cancer targets using immunocores immtac technology september roche inovio pharmaceuticals enter partnership research develop commercialise inovios multiantigen dna immunotherapies targeting prostate cancer hepatitis b november roche polyphor enter partnership develop commercialise polyphors novel antibiotic pol patients suffering bacterial infections caused multidrug resistant pseudomonas aeruginosa bacterium november roche immatics sign collaboration develop commercialise cancer vaccines cancer immunotherapies gastric lung prostate cancer december roche prothena enter worldwide collaboration codevelop copromote antibodies treatment parkinsons disease research development roche annual report taining record one industrys leading dealmakers estimated cost bringing new chemical biological partners entity market usd million also involved innovative medicines initiative joins pharmaceutical industry universities hospitals small mediumsized enterprises patient organ isations public authorities jointly funded euro pean commission pharmaceutical industry current projects cover early late stages medicine development address range topics chronic back pain anti tuberculosis drug combinations roche diagnostics signed new collaboration agreements source j mestreferrandiz j sussex towse r cost new medicine office health economics december hansen external pharmaceutical companies develop com wiggins dimasi et al ota dimasi et al panion tests drugs adding existing agreements mestreferrandiz et al also entered deal pacific biosciences califor nia develop diagnostic products including sequencing sys use new technologies develop smarter ways managing tems consumables based pacific biosciences single vast amounts data across different systems molecule realtime technology also looking innovative ways design clinical stud ies potentially determine answers earlier breaking new ground using novel surrogate endpoints improving r productivity pathological complete response early breast cancer minimal residual disease lymphomas geographic atrophy year look smart new ways improve r lesion size dry agerelated macular degeneration mag efficiency costs developing molecule bringing netic resonance enterography crohns disease market continue rise due part need screen molecules able identify potential industry collaboration called transcelerate bio new candidate well need complex clinical pharma working companies simplify trials regulatory requirements become stringent processes related clinical trial operations monitoring rethink programme multiyear initiative en compasses every aspect develop medicines conducting responsible r always resources develop new medicines patients r activities conducted highest ethical several approaches also help us contain spending standards published several position papers reducing time takes turn compound medicine r activities areas genetics stem cells animal include use new technologies creation innova research routinely review update positions tive trial designs accessing crosspharma knowledge policies research involving either humans animals external collaboration collecting data need taking account scientific developments public con help us manage entire r process effectively cerns exploring ways leverage new technologies clinical trials telemedicine mobile apps social media improve clinical trials critical determining safety efficacy efficiency clinical trials one example use social new medicines clinical trials compliant networks gather key scientific insights physicians good clinical practice guidelines international quality stan help us design trials effectively another exam dard information trials shared regulatory ple exploring use smart phones broaden authorities payers patients involved geographical reach trials future also making roche annual report research developmentroche clinical trial statistics contract research organisations working roches behalf number patients clinical trials country classification decreased compared approxi mately animals used mice rats low income middle income overall decrease animal usage reflects impact closure nutley research site new jersey usa upper middle income major research sites awarded continued full reaccredi tation status association assessment accredi high income tation laboratory animal care international aaalac source world bank underscoring commitment ensuring animal welfare based gross national income per capita low income usd less lower middle income usd usd upper middle income usd usd high income usd clinical trials trials carried high standards regardless world run clinical trials number clinical trials number healthcare centres involved number patients phase iiv clinical trials datasharing policy introduced new data sharing policy promote broad sharing clinical trial data interest scientific progress benefit patients policy includes provision clinical study reports summary safety reports access analysable patientlevel data way protects patient confidentiality respects role health authorities assessment approval drugs compromise commercial interests working compa nies develop common approach sharing patient level data animal welfare take public concern animal research seriously throughout worked maintain already high standards animal welfare wherever possible seek alter natives use animals computer simulation vitro testing using differentiated cells stem cells used animals internal research decrease number animals used research development roche annual report pharmaceuticals pipeline roche annual report pharmaceuticals pipeline pharmaceuticals pipeline roche annual report pharmapipelinefusszeilenengindd pages noitacidni tcudorptcejorp di tcejorp recnac revil bamuzutrano gr sruomut dilos bam reh gr sruomut dilos bam rfsc gr sruomut dilos hni kem gr ygolocno bam fgevgna gr sruomut dilos hni laud kem far gr sruomut meh dilos tna mdm gr amonalem faroblez bam ldp gr sruomut dilos nitsava bam ldp gr sruomut dilos binitemiboc bam ldp gr sruomut dilos bam ldp gr recnac etatsorp cda paets gr citaercnap recnac nairavo cda cum gr amoleym elpitlum cda gr ygolocno cda bipan gr ygolocno cda gr llc avyzag hni lcb gr snoitacidni meh hni lcb gr amohpmyl sruomut dilos hni khc gr sruomut dilos hni kip gr amonalem citatsatem cda rbte gr enil dn amotsalboilg hni kip gr sruomut dilos ci vli aec gr sruomut dilos gr sruomut meh gr sruomut dilos hni kip uhc enil dn cbm reh atejrep gr lma egdevire gr ccb elbarepo egdevire gr enil ts crcm bamuzutrano gr enil ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr sruomut dilos hni kip bisilitcip gr sruomut dilos hni tka bitresatapi gr enil rdn clcsn bam ldp gr ccr nitsava bam ldp gr sruomut meh cda dc nitodev bamuzutanip gr sruomut meh cdabdc nitodev bamuzutalop gr sruomut lailehtipe bam rfgereh gr ledp tcarferler llc hni lcb gr clcsn rotibihni kla binitcela gr recnac revil bam nacipylg gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksirhgih nitsava gr enil ts recnac nairavo nitsava gr evitisnesmunitalp recnac nairavo despaler nitsava gr tnerrucer recnac lacivrec nitsava gr cb ylrae reh atejrep gr recnac cirtsag reh atejrep gr recnac cirtsag reh alycdak gr enil ts cbm reh atejrep alycdak gr cb ylrae reh alycdak gr enil rdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr tum rfge l clcsn bamuzutrano gr lcbld bamuzutunibo avyzag gr despaler lhni bamuzutunibo avyzag gr eniltnorf lhni bamuzutunibo avyzag gr jda amonalem faroblez gr amonalem faroblez obmoc binitemiboc gr tcarferler llc hni lcb gr noitalumrof cs lhn arehtbam gr tnatsisertp ac nairavo ler nitsava gr enil ts amotsalboilg nitsava gr llc ag bamuzutunibo gr sesaesid enummiotua bam li gr ar bam rli uhc sisorelcs cimetsys armetca gr sisorbfi yranomlup cihtapoidi bamuzikirbel gr sitiloc evitareclu bamuzilorte gr susotamehtyre supul cimetsys bamuzilatnor gr amhtsa bamuziliuq gr sititamred cipota bam rli uhc sitiretra llec tnaig armetca gr amhtsa ereves bamuzikirbel gr ylagemorca editoertco laro gr yhtaposehtne lynevus uhc ar ylrae armetca gr noitalumrof cs ar armetca gr airacitru cihtapoidi cinorhc rialox gr vbh tsinoga rlt gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr acneuflni bam aulf gr vch rivubortes gr lairetcabitna citoibitna dtpl gr esaesid yendik gr setebaid epyt oga laud plgpig gr dvcsca bamucalcni gr sesaesid cilobatem bam kscp gr sredrosid evitingoc man aabag gr ainerhpozihcs hni aedp gr ainerhpozihcs gr yhporta ralucsum lanips recilps nms gr sremiehzla hni boam gr noisserped man ulgm gr esaesid evislupmoc evissesbo nitrepotib gr noisserped tnatsisertnemtaert man ulgm gr msitua tsinogatna rotpecer v gr sremiehzla bamuzenerc gr sremiehzla bamurenetnag gr smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihcs nitrepotib gr emdovrdma viled tsus sitnecul gr dmaw gr yhporta cihpargoeg rotcaf bamuzilapmal gr ailihpomeh bam cfiicepsib xfaxif uhc us fda submission pending rgno roche genentech managed submitted eu chu chugai managed submitted eu us filing pending rg mabthera branded approved us submitted eu rituxan us japan submitted us rg actemra branded personalised healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelated macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nhl nonhodgkins lymphoma cll chronic lymphocytic leukemia nsclc nonsmall cell lung cancer cmv cytomegalovirus ppms primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rms relapsing multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabetes hcv hepatitis c virus ygolocno noitammalfni ygolonummi suoitcefni sesaesid cilobatem ralucsavoidrac ecneicsoruen ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp ddnigneenilepipamrahpraehcorpharmaceuticals pipeline roche annual report pharmaceuticals pipeline pharmaceuticals pipeline roche annual report pharmapipelinefusszeilenengindd pages noitacidni tcudorptcejorp di tcejorp recnac revil bamuzutrano gr sruomut dilos bam reh gr sruomut dilos bam rfsc gr sruomut dilos hni kem gr ygolocno bam fgevgna gr sruomut dilos hni laud kem far gr sruomut meh dilos tna mdm gr amonalem faroblez bam ldp gr sruomut dilos nitsava bam ldp gr sruomut dilos binitemiboc bam ldp gr sruomut dilos bam ldp gr recnac etatsorp cda paets gr citaercnap recnac nairavo cda cum gr amoleym elpitlum cda gr ygolocno cda bipan gr ygolocno cda gr llc avyzag hni lcb gr snoitacidni meh hni lcb gr amohpmyl sruomut dilos hni khc gr sruomut dilos hni kip gr amonalem citatsatem cda rbte gr enil dn amotsalboilg hni kip gr sruomut dilos ci vli aec gr sruomut dilos gr sruomut meh gr sruomut dilos hni kip uhc enil dn cbm reh atejrep gr lma egdevire gr ccb elbarepo egdevire gr enil ts crcm bamuzutrano gr enil ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr sruomut dilos hni kip bisilitcip gr sruomut dilos hni tka bitresatapi gr enil rdn clcsn bam ldp gr ccr nitsava bam ldp gr sruomut meh cda dc nitodev bamuzutanip gr sruomut meh cdabdc nitodev bamuzutalop gr sruomut lailehtipe bam rfgereh gr ledp tcarferler llc hni lcb gr clcsn rotibihni kla binitcela gr recnac revil bam nacipylg gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksirhgih nitsava gr enil ts recnac nairavo nitsava gr evitisnesmunitalp recnac nairavo despaler nitsava gr tnerrucer recnac lacivrec nitsava gr cb ylrae reh atejrep gr recnac cirtsag reh atejrep gr recnac cirtsag reh alycdak gr enil ts cbm reh atejrep alycdak gr cb ylrae reh alycdak gr enil rdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr tum rfge l clcsn bamuzutrano gr lcbld bamuzutunibo avyzag gr despaler lhni bamuzutunibo avyzag gr eniltnorf lhni bamuzutunibo avyzag gr jda amonalem faroblez gr amonalem faroblez obmoc binitemiboc gr tcarferler llc hni lcb gr noitalumrof cs lhn arehtbam gr tnatsisertp ac nairavo ler nitsava gr enil ts amotsalboilg nitsava gr llc ag bamuzutunibo gr sesaesid enummiotua bam li gr ar bam rli uhc sisorelcs cimetsys armetca gr sisorbfi yranomlup cihtapoidi bamuzikirbel gr sitiloc evitareclu bamuzilorte gr susotamehtyre supul cimetsys bamuzilatnor gr amhtsa bamuziliuq gr sititamred cipota bam rli uhc sitiretra llec tnaig armetca gr amhtsa ereves bamuzikirbel gr ylagemorca editoertco laro gr yhtaposehtne lynevus uhc ar ylrae armetca gr noitalumrof cs ar armetca gr airacitru cihtapoidi cinorhc rialox gr vbh tsinoga rlt gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr acneuflni bam aulf gr vch rivubortes gr lairetcabitna citoibitna dtpl gr esaesid yendik gr setebaid epyt oga laud plgpig gr dvcsca bamucalcni gr sesaesid cilobatem bam kscp gr sredrosid evitingoc man aabag gr ainerhpozihcs hni aedp gr ainerhpozihcs gr yhporta ralucsum lanips recilps nms gr sremiehzla hni boam gr noisserped man ulgm gr esaesid evislupmoc evissesbo nitrepotib gr noisserped tnatsisertnemtaert man ulgm gr msitua tsinogatna rotpecer v gr sremiehzla bamuzenerc gr sremiehzla bamurenetnag gr smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihcs nitrepotib gr emdovrdma viled tsus sitnecul gr dmaw gr yhporta cihpargoeg rotcaf bamuzilapmal gr ailihpomeh bam cfiicepsib xfaxif uhc us fda submission pending rgno roche genentech managed submitted eu chu chugai managed submitted eu us filing pending rg mabthera branded approved us submitted eu rituxan us japan submitted us rg actemra branded personalised healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelated macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nhl nonhodgkins lymphoma cll chronic lymphocytic leukemia nsclc nonsmall cell lung cancer cmv cytomegalovirus ppms primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rms relapsing multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabetes hcv hepatitis c virus ygolocno noitammalfni ygolonummi suoitcefni sesaesid cilobatem ralucsavoidrac ecneicsoruen ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp ddnigneenilepipamrahpraehcorpharmaceuticals division major clinical trials product indication trial phase outcome aleglitazar metabolic diseases alecardio independent data safety monitoring board dsmb phase iii recommended trial halted due safety signals lack efficacy avastin advanced cervical gog study met primary endpoint improving overall survival cancer phase iii statistically significant reduction risk death women received avastin plus chemotherapy compared received chemotherapy alone avastin metastatic nonsmall beyond people received avastin plus chemotherapy benefited cell lung cancer phase iii significant improvement progressionfree survival compared first line china received placebo plus chemotherapy etrolizumab moderatetoseverely eucalyptus study met primary endpoint clinical remission showed active ulcerative colitis phase ii well tolerated clinically significant safety concerns gazyva chronic lymphocytic cll stage gazyva plus chlorambucil improved overall survival leukemia phase iii compared chlorambucil alone stage gazyva plus chlorambucil significantly reduced risk disease worsening death compared mabthera rituxan plus chlorambucil people previously untreated chronic lymphocytic leukemia kadcyla herpositive thresa kadcyla significantly extended time people advanced metastatic phase iii herpositive breast cancer lived without disease worsening breast cancer compared people received treatment physicians choice openlabel study lampalizumab advanced dry macular mahalo study met primary endpoint change area geo degeneration eye phase ii graphic atrophy patients advanced form dry age geographic atrophy related macular degeneration amd strongest treatment effect observed patients positive complement factor cfi genetic biomarker tarceva nonsmall cell lung radiant study meet primary endpoint improved diseasefree cancer phase iii survival dfs tarceva show improvement dfs adjuvant treatment patients surgicallyresected nsclc compared placebo xolair chronic idiopathic asteria ii xolair met primary endpoint patients moderate severe urticaria phase iii chronic idiopathic urticaria remained symptomatic despite glacial treatment approved h antihistamine doses phase iii pharmaceuticals division major regulatory filings product clinical data supporting filing indication dosage form country actemra function phase iii early rheumatoid arthritis eu alectinib japanese phase iii study alkfusion genepositive unresectable recurrent japan japiccti advanced nonsmall cell lung cancer avastin aurelia phase iii platinumresistant ovarian cancer eu avastin avaglio phase iii glioblastoma eu avastin beyond metastatic nonsmall cell lung cancer first line china gazyva cll phase iii chronic lymphocytic leukemia us obinutuzumab cll phase iii chronic lymphocytic leukemia eu xolair asteria ii phase iii chronic idiopathic urticaria us roche annual report research developmentpharmaceuticals division major regulatory approvals product clinical data supporting filing indication dosage form country actemra summacta phase iii brevacta rheumatoid arthritis us ubcutaneous phase iii actemra summacta phase iii brevacta rheumatoid arthritis japan ubcutaneous phase iii musashi phase iii matsuri phase iii actemra cherish phase iii polyarticular juvenile idiopathic arthritis us eu roactemra avastin ml phase iii metastatic colorectal cancer tml treatment us across multiple lines avastin brain phase ii jo phase ii newly diagnosed relapsed glioblastoma japan avaglio phase iii avastin gog phase iii icon phase iii ovarian cancer japan erivedge erivance bcc phase ii advanced basal cell carcinoma eu conditional approval herceptin hannah phase iii prefher phase ii herpositive breast cancer eu ubcutaneous gazyva cll phase iii chronic lymphocytic leukemia front line us kadcyla emilia phase iii herpositive metastatic breast cancer us eu second later lines japan lucentis harbor phase iii inclusion less frequent dosing regimen us wet agerelated macular degeneration mabthera rave phase iii active gpa mpa two types eu rituxan ancaassociated vasculitis pegasys peds c phase iii chronic hepatitis c children five years eu age older perjeta cleopatra phase iii herpositive metastatic breast cancer eu japan first line perjeta neosphere phase ii herpositive breast cancer neoadjuvant us accelerated approval tarceva eurtac phase iii egfrmutationpositive nonsmall cell lung us cancer first line research development roche annual report roche diagnostic tests personalised treatments market late development disease area disease drug diagnostic test technology application virology cmv valcyte cmv viral load pcr monitoring hbv pegasys hbv viral load pcr monitoring antivirals hbv pegasys peginterferon hbsag levels immunoassay monitoring alfab mercksp hcv pegasys peginterferon hcv viral load pcr monitoring alfab mercksp hcv mericitabine r hcv viral load pcr monitoring hcv danoprevir rg hcv viral load pcr monitoring hiv antivirals hiv viral load pcr monitoring hiv abacavir glaxosmithkline hlab genotype pcr screening oncology breast cancer herceptin kadcyla perjeta expression ihc ish selection gene amplification breast cancer tamoxifen erpr expression ihc selection hormonal therapies cancer compound merck p mutations microarray selection colon cancer cetuximab merck kras mutations pcr selection panitumumab amgen gastric cancer herceptin expression ihc ish selection gene amplification lymphoma brentuximab vedotin cd expression ihc selection seattle geneticsmillennium melanoma zelboraf cobimetinib rg braf mutation pcr selection nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc onartuzumab met expression ihc selection metmab rg nsclc antipdl rg pdl expression ihc selection nsclc tg transgene muc expression ihc selection inflammation asthma lebrikizumab rg serum periostin immunoassay selection levels rheumatoid arthritis mabtherarituxan rf anticcp ab immunoassay selection ophthalmology geographic atrophy lampalizumab cfiexpression pcr selection neuroscience alzheimers disease gantenerumabrg levels immunoassay selection projects pharmaceutical companies disclosed confidentiality reasons available markets selection patients eligible firstline treatment black type market grey type development monitoring monitoring patients response particular treatment screening screening patients particular genetic variation hlaassociated hypersensitivity abacavir selection selection patients eligible particular treatment anticcp ab antibodies cyclic citrullinated peptide braf bisoform rapidly growing fibrosarcoma oncogene cfi complement factor cmv cytomegalovirus egfr epidermal growth factor receptor erpr estrogen receptorprogesterone receptor hbv hepatitis b virus hbsag hbv surface antigen hcv hepatitis c virus human epidermal growth factor receptor hiv human immunodeficiency virus hla human leucocyte antigen ihc immunohistochemistry ish situ hybridisation kras member ras family oncogenes met methioin muc member mucin glycoprotein family pcr polymerase chain reaction rf rheumatoid factor sp scheringplough roche annual report research developmentdiagnostics division major product launches area product name description market instrumentsdevices laboratories cobas nextgeneration modular preanalytics eu diabetes care accuchek active test strips accuchek active test strips ww maltoseindependent chemistry excluding na life sciences gs flx long amplicons software longread targeted sequencing ww testsassays oncology calcitonin test medullary thyroid cancer eu progrp test small cell lung cancer eu cobas egfr test nonsmall cell lung cancer stratification us er primary antibody ivd immunohistochemistry test determining us state hormone receptor breast cancer tissue cintec plus cytology cervical precancer test eu infectious diseases capctm hcv nextgeneration hcv viral load test us transplantation elecsys cyclosporine immunosuppressive drug monitoring eu tacrolimus tests sequencing seqcap ez reagent kits singlesource reagent kit ww diagnostics division key product launches planned area product name description market instrumentsdevices laboratories cobas next generation molecular pcr system ww cobas fully integrated automated hematology system eu cobas automated urinalysis work area eu connectv middleware providing connectivity lis ww diabetes care accuchek insight next generation insulin pump bgm system eu accuchek connect bg meter connectivity smartphones eu mobile app cloud testsassays blood screening mpx next generation blood screening multiplex test us infectious diseases mpx hiv hcv hbv hev full nat blood screening menu cobas ww dpx wnv hiv hcv hbv virology tests cobas ww hsv detection herpes simplex virus cobas eu syphillis immunoassay detection treponema pallidum eu microbiology mrsasa next generation test cobas eu cdifficile diagnosis clostridium infections eu womens health amh assessment ovarian reserve fertility eu pe prognosis claim extension shortterm prediction eu preeclampsia pregnancy excluding us hospital information systems blood glucose monitoring parvovirus b hepatitis virus west nile virus research development roche annual report helping fight hepatitis b roche business report making innovation accessiblechina million people chronically infected hepatitis b virus hbv worldwide around million live china hbv main cause chronic liver disease cirrhosis primary liver cancer number patients chronic hbv infection treated pegasys bringing stateoftheart therapy patients people hepatitis often unaware infection simply access treatment china order help situation roche established diagnostic capacity medical training improve knowhow wider access correct treatment regimes pharmaceuticals diagnostics divisions work closely together ensure right treatment offered right patient given preva lence hepatitis b china vital identify patient subgroups likely benefit targeted therapy result patients see improved outcomes integrated approach means patients quality life enormously improved resources used optimally making innovation accessible roche annual report manufacturing sites roche annual report manufacturing procurement approved million swiss francs investment biologic production capacity enabled rapid launches kadcyla gazyva conducted sustainability audits suppliers high level compliance confirmed roche annual report manufacturing procurement key figures manufacturing sites pharmaceuticals diagnostics joint sites portfolio medicines reagent kits instruments manufacturing procurement supply functions contin medicines roche pipeline equipment refur ued support rapid development new roche medicines bishment diagnostic tests priority review status breakthrough basel switzerland million swiss francs therapy designations new products like kadcyla build antibodydrug conjugate adc production facility gazyva represented important recognition provide additional capacity flexibility breakthrough medicines also resulted shortened vacaville oceanside united states around mil timelines launch similarly set ambitious time lion swiss francs increase biologic manufacturing ca lines launches new diagnostic products pacities including commissioning previously idled cobas system internally meant continuously second bulk drug production unit genentechs vacaville shortening timespans launch bringing products facility patients customers particularly manufacturing supply expect create approximately new jobs investments launching new products maintaining quality supply patients meeting demand underlying growth business biologics manufacturing strategy includes internal key priorities manufacturing procurement sup external network help ensure agility flexibility ply operations throughout functions supported address demand uncertainty supply resiliency addition strong sales growth new existing products en investments internal network biologics abling roche strengthen leadership oncology manufacturing strategy includes establishing strategic part biotechnology vitro diagnostics continued focus nerships select targeted reliable external manufacturing supply existing products meeting stringent organisations health authority requirements maintaining reliable deliv ery customers support areas including r pipeline also remained priority stream pharmaceuticals lining network capital investment support busi ness priorities network pharmaceutical manufacturing network produces medicines clinical trials commercial supplies investments future worlds sophisticated biopharmaceuti cal production plants network hosts approximately year board approved million swiss francs global biologic production capacity making roche larg investments global pharmaceuticals manufacturing est manufacturer biotech sector network investments span next five years increase production capabilities biologic medi cines providing strong foundation deliver investiga tional biologic medicines pipeline invest penzberg germany approximately million swiss worldwide mammalian cell culture capacity including contract manufacturing organisations bioplan associates inc annual report francs support delivery investigational biologic internal analyses roche annual report manufacturing procurementmanufacturing sites roche group pharmaceuticals mannheim diagnostics penzberg basel kaiseraugst rotkreuz segrate clarecastle hillsboro indianapolis branford south san francisco vacaville branchburg legans utsunomiya tucson florence yokneam illit shanghai fuju iek dim aa oceanside toluca ponce singapore rio de janeiro performance also took decision phase production growing number projects pipeline requires dili operations toluca mexico regular assessment gent planning across manufacturing network ensure worldwide manufacturing network revealed significant successful commercialisation innovative approaches continued underutilisation facilities next technical development increased rate four years reduce production close manufac success also facilitated launch kadcyla day turing site approval gazyva one working day approval maintaining highest standards quality patients recognising opportunities challenges posed pharmaceuticals pipeline launched project increase capability capacity commercialise new products project currently investigating range aspects including resource planning deployment launch site strategy speeding processes involved commercialising new molecule manufacturing procurement roche annual report pipeline patient faster data accelerated approval timeline beginning sub ever mission fda april may fda given gazyva breakthrough therapy designation priority review originally gazyva launch scheduled june accelerated fda approval process gazyva ga received fda approval eight months earlier obinutuzumab new medicine treat chronic lymphocytic originally expected friday november pharma leukemia underlines importance new treatment came ensuing challenges working throughout year patients however speed approval came signifi manage continuously shortening time period launch day cant operational challenges many years research gazyva available patients one working day approval development phase iii data gazyva became available granted us authorities spring showing significant medical benefits positive research early development clinical development commercialisation market phase iii approval process phase iv months originally scheduled leadtime application filing us regulatory approval months research early development clinical development commercialisation market phase iii approval process phase iv months gazyva months us fda filing april us fda approval november diagnostics performance achieved goals saving costs maintain network ing supply products meet divisions abovemarket manufacturing network roche diagnostics handles sales growth production logistics industryleading portfolio vitro diagnostic products includes stateoftheart delivered million test kits elecsys immuno instruments different reagent kits different assay product line run automated testing systems types consumables pipettes cuvettes billion tests conducted kits roche diagnostics offered five billion also supported launch major diagnostic products consumables key markets including cobas four new cancer tests manufacture majority instruments tests inhouse allows us maintain cost quality advan completed transfer chemical operations mann tages leverage proprietary technologies special ex heim germany site penzberg germany con pertise use external manufacturers needed access tract manufacturers additionally closed burgdorf unique technologies control costs example pro switzerland site january transferring operations duction handheld blood glucose meters large work sta mannheim tions consumables increasing number sub assemblies roche annual report manufacturing procurementlocal projects increase focus increasing local capabilities believe access healthcare provides sustainable way address health needs develop healthcare systems future working egyptian government example roche producing pegasys manufacturing experts working number countries herceptin mabthera locally different trade names second brand initiatives products packaging packaged distributed locally products rebranded versions original brand manufactured production sites original subject quality control procedures partnering local manufacturers endstage manufactur ing second brands helps strengthen local manufacturing capabilities increases local skills provides employment programmes range training healthcare profession als helping establish clinics laboratories strength ening local manufacturing capabilities supply chains also continued restructuring roche diabetes care capital investment year sustain longterm profitability diabe throughout focused expanding capacity im tes care market remains challenging however see tremen proving efficiency manufacturing network dous growth opportunities believe well posi penzberg germany increasing raw material pro tioned remain leading provider space mass duction elecsys immunoassays building diagnos production capacity seven billion strips per year tics production complex project represents highlevel quality favourable cost structure based investment approximately million swiss francs started inhouse outsourced manufacturing march expected completed mannheim germany investing million swiss also made progress several longterm francs additional production capacity supporting clini initiatives including supply chain excellence direct cal chemistry immunochemistry product lines including procurement excellence projects aimed sustainable high new production facility performance included maintaining continuous im prove ment culture supporting metrics manufacturing quality performance well introduction methodolo gies tools ensure robust production processes also initiated activities adapt distribution processes planning network improve customer satisfac tion distribution expenses inventory levels quality com pliance verified internal audits within diagnostics division total manufacturing sites successfully managed inspections regulatory authorities notified bodies registrars critical issues identified manufacturing procurement roche annual report started harmonise payment terms across group reduce trade working capital activities completed supplier day china divisions continued improve value efficien second supplier day china brought together cies year number key activities participants learn sustainability improving organisational structures capabilities man roche supplier audits following event many suppliers age spend improved sustainability standards committed com developing category roadmaps strategies spend plying roche supplier code conduct well joint diagnostics pharmaceuticals category manage working closely roche innovation anticorrup ment teams tion risk management recycling priority areas developing longterm category strategy category increased focus sustainability yielded one roadmap better match pharma business requirements million swiss francs direct benefits past three suppliers capabilities years chinese suppliers audited continuing direct procurement excellence programme completed agreed followup diagnostics improve management supplier network risk management already delivering results engaging suppliers believe supplier engagement critical number reasons managing performance risk effectively ensuring quality compliance reducing combined environmental footprint fostering innovation end num ber initiatives place strengthen relationships sup pliers one example roche supplier relationship center south san francisco united states opened bringing together roche procurement staff five strategic suppliers seek opportunities innovation prod uct development new processes recycling risk reduction supplier relationship center delivers results supplier relationship center completed pilot phase manufacturing improvement initiatives procurement deliver significant savings roche selected partners provide packaging components singleuse technology pro procurement teams continue pursue variety duction filters chromatography resins well approaches strengthening business units generating take contract manufacturing roche products cost savings reinvested business also collaborated supplier introduce external phar also improving capabilities meet demands maceutical sector programme increases environmental growing number projects pharmaceuticals pipeline compliance whilst reducing audit workload centre expanded include suppliers product develop aligning building capabilities ment areas procurement roche organised division mirroring structure business facilitate highest level establishing formal supplier relationship management support also closely coordinate procurement policies process roche achieving systematic classification sup processes systems largevolume spend across group pliers enables focus critical strategic suppliers strengthening alignment development resulting closer relationships improved performance groupwide procurement policy implemented risk management roche annual report manufacturing procurementmonitoring compliance tions ability manage quality performance exchange also updated supplier elearning module best practices across networks roche supplier code conduct making available five languages completed supplier supply chain management representatives date commitment quality innovation sustainability ex tends throughout supply chain responding quickly close collaboration suppliers also reflected market developments ensuring reliable endtoend prod findings supplier audits high levels compliance uct supplies reducing environmental footprint main roche industry codes standards tain highly integrated responsive global supply chains divisions also continue investigate implement conducted sustainability audits suppliers enhancements processes worldwide compared suppliers directly involved supply chain dedicated project involving whole planning providers goods services majority com munity deliver improved streamlined pro audited suppliers located latin america asiapacific cesses major project aimed improving work pro eastern europemiddle east terminated business cesses focusing stabilising delivering reliability two suppliers meet minimum standards operations new focus establishing technical pro duct prepared improve management taking shape progressed sig nificantly also intensified collaboration pharma suppliers ceutical supply chain initiative psci able access supplier audit reports via psci addition started provide raw materials global rollout anticorruption compliance questionnaire logistic services packaging research services marketing services quality compliance across continents overriding goal ensure every person receives countries safe roche medicines reliable diagnostic test results many cultures achieve apply rigorous standards wherever help us manufacture medicines roche product manufactured sourced additionally deliver customers diagnostic tools ensure quality management systems conform patients different reagent kits laws regulations well current norms stan dards cgmp ich iso roche continued global harmonisation en hancement quality management systems pharma ceuticals division established new system global standards areas quality management risk manage ment preventive corrective actions local imple mentation ongoing diagnostics divisions efforts har monise multiple quality systems complete yearend harmonisation expected drive compli ance efficiency enhancing manufacturing organisa current good manufacturing practices cgmp international confer ence harmonisation technical requirements registration pharmaceuticals human use ich international organization standardization iso manufacturing procurement roche annual report overcoming hurdles improve access treatment roche business report making innovation accessibleegypt million people egypt around infected hepatitis c virus additional new infections per year represents major threat public health second brand pegferon allows broader access treatment egypt option target medical care right patients enables healthcare providers optimise use resources available second brand increase access care medical benefit affordability treatment significant problem egypt order address roche introduced pegferon second brand hepatitis treatment pegasys medicine first brand packaged locally vial form allows roche sell medicine lower price government result increased access treatment country roche completes offer products diagnosis treatment monitoring helping maximise medical service patient benefit making innovation accessible roche annual report patients treated one roches top selling products roche annual report markets piloted innovative pricing models europe hosted top oncologists japan discuss advanced cancer therapies supported indepth study state cancer care countries roche annual report markets key figures sales main markets usa million chf europe million chf japan million chf e brazil china india mexico russia south korea turkey million chf growth rates constant exchange rates average fullyear roche supplies medicines diagnostic tests geted medicines treat subgroups patients countries worldwide however healthcare systems vary signif tested confirm likelihood response therefore icantly country country even within countries significant advantages payers personalised health countries sophisticated medicines diagnostic tests care known roche core innovation strategy readily available whilst others healthcare infrastructure number diseases medicines companion limited basic medical care still luxury diagnostic tests identify subgroups bringing greater precision treatment better value healthcare recognising disparities different approaches payers added personalised healthcare port help break barriers good healthcare take folio launch personalised breast cancer medi longterm view markets working closely local cines kadcyla perjeta well us approval health authorities healthcare providers develop tarceva companion diagnostic test firstline therapy ways bring medicines tests many patients lung cancer possible aim every person needs products able access benefit postauthorisation assessment development many markets increased adoption postlaunch assessments emphasis put real life evidence comparative effective medical value ness safety economic impact medicines frequently assessments linked reevaluation pricing developing products significantly improve peoples lives reimbursement conditions central premise business believe bringing innovative products markets demonstrating clear roche member tapestry networks working group medical value healthcare providers fundamental sus postlaunch value assessments international group tainable success end actively involved con comprising patients clinical experts healthcare providers tributing health technology assessments htas reimbursement agencies payers healthcare policy healthcare authorities systematically evaluate medical ben makers propose guidelines assessments efit medicines diagnostic tests relation group published recommendations effective investment decision framework guiding evidence generation new medicine registered launched hta personalised healthcare hta continues become increasingly sophisticated wide parallel also aligning organisations internally spread countries adopting systems improve ability engage healthcare policy decision better assess medical economic value medicines tar roche annual report marketsmakers stakeholders evaluation real disease world impact products awareness h c tacu klins gt ao dim versi es se et cs hao llel nu gest ao ndn dys namics different ur oc se es r mit mm oe cnt imp uo tv ce od h ee salth e etlt sh yc er gf nu nc oit healthcare systems requires significant longterm commitment fully understanding needs issues given diagnostic tools country decentralised business model em medicines powers local management work closely local health care providers determine best customise solutions appropriate market conditions fundamental markets premise must bring disease mean patient needing combination real medical value patients healthcare providers medicines led us rethink pricing models help ensure many people possible access develop call personalised reimbursement models medicines tests requires tailoring strategy models allow us differentiate value medicine market develop models effective within given indication either multiple indication individual healthcare systems often involves providing pricing valuebased pricing additional clin comprehensive array solutions range ical economic value treatment affordability programmes strengthening local infrastruc ture working groups provide effective personalised reimbursement models patient education support programmes personalised reimbursement models potential significant value stakeholders speeding access innovative pricing models innovative treatments patients reducing financial believe pricing models future move away pressure clinicians prescribing options enabling volumebased approach towards valuebased one pricing better reflect value treatment however price determined effectiveness implement kind model need able track medicine treatment progress science brought us use products requires close collaboration products treat variety indications response healthcare providers well supporting infra treatment different indications vary considera structure share data without impacting patient confiden bly also often one approach tackling tiality new pricing models move volumeto valuebased pricing today future unitbased pricing personalised reimbursement models reimbursement driven volume therapy used reimbursement driven value therapy delivers patient price differentiated indication undifferentiated price per vial price differentiated combination price differentiated treatment course markets roche annual report roche began piloting number projects exter another way differentiate prices introduc nal healthcare providers europe assess pricing tion second brands products second brands models practice italy similar system already original product commercialised successfully place since multiple indication different names come slightly different forms pricing introduced number products example vials rather syringes example expecting countries move direction india roche developed second brands cancer anticipate able expand access drugs herceptin mabtherarituxan well hepatitis medicines focusing value effectiveness medicine pegasys patients patient assistance programmes differential pricing also recognise many patients even developed access good healthcare particularly emerging markets countries still afford treatment even vary considerably afford may insurance may able pay treatment fully access stateoftheart private care often majority covered individual insurance plans reason roche reliant poorly funded public healthcare system provides patient assistance programmes help address disparity piloting number differential underinsured uninsured access medicines pricing models involve reducing prices patients united states example genentech access solutions pay andor governments medi helped underinsured uninsured pa cines prescribed public healthcare systems tients access appropriate medicines programmes making innovation accessible selection projects action area progress strengthening diagnostics capabilities africa technicians trained countries roche scientific campus johannesburg south africa patent filed enforced lowincome countries roche file enforce patents least developed medicines countries support children type diabetes tanzania cameroon healthcare professionals trained children uganda guinea enrolled changing diabetes children programme drc ethiopia partnership novo nordisk world diabetes kenya india foundation international society pediatric adolescent diabetes patient assistance programme treating china patients accessing herceptin programme herpositive breast cancer roche donates half treatment training lab technicians testing asia healthcare professionals trained countries awareness campaign hepatitis c testing brazil tests administered patients promote early diagnosis receiving treatment result second brands key medicines made egypt ukraine patients treated second brands available lower cost india p akistan collaboration insurance providers china policies sold since project began develop health policies cover cancer helping uninsured underinsured us patients supported genentech access patients access roche products solutions mobile mammography units screen algeria morocco screened since programme began women rural areas north africa tunisia alone breast cancer team medical educators travel across saudi arabia project outreach screened women breast cancer remote areas raise awareness cancer well organised symposium doctors improve screening cancer diagnosis roche annual report marketsunderstanding roche integrating insights report dialogue challenges cancer care cancer experts policy makers potential partners find solutions oncology care challenges highlights developing world higher income countries one last years global cancer burden doubled international forum held uicc world set double increase cancer leaders summit cape town south africa expected come low middleincome countries facilitated discussion wide range stakeholders access care severely limited comprehensive work affect change discussions helping publicprivate partnerships needed order make formulate ideas strategies improve access cancer care progress necessary address situation around world conclusion state oncology report professor peter boyle epidemiologist president international prevention research institute multidisciplinary group experts report took nearly two years research complete funded roche unrestricted educational grant ensuring findings completely independent looks detail oncology care countries across eight regions calls urgent action governments pharmaceutical industry society come together improve oncology care education healthcare involve working collaboration payers nonprofit organisations deliver free medicines patients professionals access treatment also continue treatment complete full course another key area activity markets support strengthening infrastructure education healthcare professionals believe many areas world healthcare infrastructure rudi understanding medical practitioners prod mentary significant challenges exist lim ucts current thinking way used treat ited fiscal constraints basic level disease better treatment patients facili critical shortages medical professionals health facilities tate produce broad range educational training low awareness causes symptoms prevention materials well host support medical congresses treatment disease even poor electricity supplies events roche also committed providing medical educa keep hospital equipment running help resolve issues tion new therapeutic areas significant unmet roche collaborates local stakeholders governments need one example schizophrenia par international health organisations support education ticularly active supporting education bringing together development healthcare infrastructure well improve expertise disease availability medicines provide diagnostic tests markets roche annual report education healthcare professionals selection examples area activities improving understanding new emerging clinical data european cancer congress american society clinical oncology improving understanding advances treatment th international transplant infectious disease conference austria diagnosis summer school parkinsons disease united kingdom european restless legs syndrome study group annual meeting germany innovations meeting portugal training doctors nurses healthcare providers online classroom training sessions treatment options safety concerns product use pediatric cystic fibrosis quality control supporting patients another key roche initiative bring together families patient groups countries asia singapore two day training workshop first roche event kind region aim event educate groups roche selling medicines tests effective public policy arena well believe critically important provide much support provide best practice examples parts world patients families work closely basis developing ideas relevant region patient groups even clinical trial phase deepen understanding impact medicines patients interactions patients believe transpar also support patient groups efforts change pub ency essential publicly declare patient group lic policy provided grant bring together key relationships activities rochecom also disclose opinion leaders policy makers psychiatrists patient groups financial nonfinancial support recommended healthcare providers make six key recommendations european federation pharmaceutical industries asso public policy schizophrenia year also ciations efpia hosted roundtable summit south america bringing gether patient groups government clinicians address also believe healthcare education awareness challenges accessing cancer care region important patients wellbeing proper medical develop roadmap policy changes next years diagnosis treatment end run many programmes improve situation support patients including counselling services screening supporting patients families selection examples patient support initiative examples purpose take cancer personally international series roundtable events publications key stakeholders oncology innovation initiative including patient groups policy makers patient advocates doctors payers public policy broaden access cancer care international working group roundtable event new york usa patient advocates groups policy makers social inclusion academia medical professionals look ways improve social inclusion schizophrenia patients people affected schizophrenia wwwaccuchekconnectcom tools resources living diabetes well clinical evidence case studies healthcare professionals wwwkadcylacom support patients taking kadcyla breast cancer roche annual report marketsprogrammes website medication reminding telephone help lines access medical professionals advise living disease handling side effects treatment improving cancer patient groups academy sends several patient group treatment japan leaders annual meeting international experience exchange patient organizations sponsored roche request attendees meeting help improve cancer treatment japan chugai member academy established japan experience exchange patient roche group established chugai academy ad organization develop support projects vanced oncology chaao fully independent nonprofit organisation improves access best practices oncology doctors researchers well patient groups doctors researchers academy organises annual conference exchange latest developments cancer ther apy around japans top oncologists attended hear worldclass experts advanced cancer therapies research academy publishes conference proceedings cost supports organises symposia local commu nities unable attend annual conference markets roche annual report working together make healthcare budgets go roche business report making innovation accessibleeurope personalised reimbursement models future patient p che infrastructure h rm increased ro ret qo n u c ira esp h dt u drr aee ta sic ct oa llk ae bh oo rl ad te ior n v pra il cu ie n gbased r eyap naicinilc developing personalised reimbursement models europe roche working develop personalised reimbursement models reflect value treatments bring patients pilot projects running number countries move pricing volume valuebased pricing reimburse ment vary depending indication combination medicines approach early stages data systems analytics systems still developed believe enormous potential patients well healthcare industry whole making innovation accessible roche annual report swiss francs support patient organisations roche annual report responsible business strengthened compliance new working model pharmaceuticals increased transparency new clinical trials data sharing policy defined new materiality process roche annual report responsible business key figures contributions healthcare institutions million chf contributions patient organisations million chf roche demand high standards ethics integrity division supported medical compliance office employees business partners commit ensures integrated aligned coordinated medical ment responsible business behaviour goes beyond strict compliance strategy furthermore reinforced system legal compliance forms basis sustainable business monitors provides global oversight medical affairs ability create longterm value stakeholders standards medical compliance across affiliates roche group known affiliate passport provide metrics evaluated activities local safety regulatory medical affairs well act highlevel issue identification strengthening compliance benchmarking tool focused heavily strengthening compliance confident measures reinforce internal particular external relations stakeholders open structures support aim ensure products dialogue discussion important us critical used best possible result patients ensure dealings external stakeholders con ducted high standards integrity code conduct issued new directive integrity spec also increasing regulatory focus profes ify clarify expectations outlined roche group sional compliant conduct scientific collaboration code conduct focuses four areas interaction medical practitioners particular response bribery granting advantages taken decision implement new work gifts entertainment ing model across pharmaceuticals organisation dealing business partners defines medical commercial accountabilities model conflict interest clearly differentiates nonpromotional activities medical scientific nature intent led account aim make sure ambiguity guide ability medical affairs promotional activities com lines clear employees topics recognise mercial marketing intent conducted leadership could lead loss business cases commercial teams new model implemented ever convinced integrity fundamental across countries activities personnel bud sustainability success business employees gets reallocated either medical commercial imple required complete training new directive mentation completed end affiliates middle addition training employees operating new model already receive code conduct addition also strengthened global oversight also launched new roche group code con medical compliance across global functions affiliates duct help advice line employees call email seek roche group ensure uniform standards worldwide help advice areas could uncertainty established medical compliance committee chaired interpret code aim foster culture chief medical officer governance oversight openness ask questions order help prevent behaviour body medical compliance good clinical practice could breach code also serves platform good pharmacovigilance practice across pharmaceuticals ideas suggestions externally advice service roche annual report responsible businessfor business partners contact roche help patient confidentiality commercially sensitive infor advice report noncompliant situation mation protected view highquality analysis clinical trial data scientific researchers broaden code conduct adhered everywhere operate knowledge medicines benefit patients including places local laws less stringent public health also expect business partners comply integrity standards supplier code conduct rochere healthcare institutions patient groups lated business transactions roche chief compliance another area committed providing greater officer primary contact external stakeholders transparency donations healthcare professionals institutions well patient organisations believe perceived actual breach code important work closely healthcare professionals conduct line management local compliance officers patient groups areas particular expertise chief compliance officer serve contacts handle provide support education fund many kinds issue alternatively employees report noncompliance activities ranging seminars professionals better issues anonymously roche speakup line understanding new medical data sponsoring workshops accessible countries languages educational seminars patient groups also tolerate retaliation employees raised started consolidate funds go directly healthcare compliance concern good faith received professionals events medical congresses notifications alleged violations code conduct line commitment sunshine act expect via speakup line report end march chief compliance officer also received estab public policy lished channels business ethics reports areas roche active consulting governments industry fraud theft violation good marketing practices conflict bodies regulatory authorities stakeholders interest discrimination harassment allegation think tanks academic institutions help shape debate carefully investigated resulting termination develop effective laws regulations policies public employment contracts account unethical behaviour health key areas discussion eu agreements business partners reason new laws policies related clinical trials personalised healthcare regulation medical devices vitro diagnostic tests critical part roches business eu also consultation pharmaceutical industry increasing transparency number issues including data protection falsified medicines pharmaceuticals environment also roche believe transparency critical pro influence policy membership industry bodies ductive responsible business environment national regional international level focused clinical trial data sharing aim forefront industry standards clinical trial results united states genentech actively monitoring shaping already reported rochetrialscom clinicaltrialsgov reacting public policy debates affecting industry well published journals congresses however state federal levels government landscape new policy expand new policy heavily influenced implementation health providing access global clinical study reports request care reform continued debate around well january researchers also receive access us debt crisis genentech worked closely various stake patient level data global clinical trials holders industry bodies allies influence requests reviewed independent panel debates key issues insurance coverage expan experts access given independent panel sion biosimilars drug safety security corporate tax basis good scientific merit patient level data payment delivery reform anonymised respect privacy patients participating trials line relevant laws regulations employees working government officials expected follow good practice guidelines act appropri expansion policy global commitment increas ate ethical professional manner ing transparency clinical trial information ensuring responsible business roche annual report associations political institutions nonfinancial reporting roche remains independent political affiliation roche committed triple bottom line principle driving social environmental performance switzerland spend around million swiss diligence financial performance francs includes payments interpharma economie reporting perspective guidelines evolving towards inte suisse scienceindustries swissholdings various cham grated reporting fully committed kind bers commerce financial assistance trade unions integrated thinking internally assessing donations political parties cantonal federal level best approach appropriate communications donations political parties lowdoubledigit channels roche stakeholders based sess thousand franc sums overall less total contri ment decided move voluntary global butions donations reporting initiative g standard order enhance social reporting engagement employees united states make personal politi cal contributions roches good government commit particular aspect new guidelines materiality assess tee genentechs political action committee genenpac ment analysis areas relevance potential oppor voluntary political action committees employ tunity risk ability preserve create ees donated us dollars political campaigns value short medium long term already apply committees materiality framework safety security health environment management actively assess impact including financial sustainability initiatives contributions healthcare institutions could business see chapter total amount million swiss francs report company whole process implementing broader materiality assessment education healthcare professionals process effectively systemise existing analysis education general public opportunities stakeholder feedback risks believe material roche research formal materiality exercise began internally roche corporate sustainability committee network six key corporate responsibility material topics contributions patient organisations identified provide basis beginning fuller total amount million swiss francs materiality assessment stakeholders access healthcare educational grants compliance corporate governance workshops seminars meetings ecoefficiency leadership employee engagement treatment adherence projects safety product plant supply chain partners disease awareness general education information areas found rele vant sections report markets corporate governance people roche annual report responsible businessthe roche materiality process universe trends issues healthcare sector business related long list materiality criteria short list revenue increase universe potential issues criteria assess materiality strategic material issues considered issues internal roche deal risk management external stakeholders strategic prioritisation reputation materiality drivers business impact stakeholder expectations concerns ability influence opportunity differentiation managing risk crisis services group bcm policy guideline place facilitating consistent aligned local implementation place full risk management policy sets currently rolling new bcm framework across approach identifying managing reporting internal group make sure roches operations resilient external risks also use stakeholder feedback help capable effectively responding major disruptions manage social environmental economic risks sustainability risk using consistent methodologies processes routinely roche adopted new business sustainability risk perform risk assessments levels organisation assessment approach order ensure emerging social group risk report covers material risks annually environmental economic risks overlooked busi discussed corporate executive committee ness sustainability risks include risks affecting multiple parts audit committee board directors regularly company well risks may longerterm impact date risk management processes raise awareness understanding risk throughout roche group approach allows us assess emerging risks annual basis integrate existing group risk group risk management team provides advisory services management process using approach potential business sites affiliates project product teams monitors risk sustainability risks identified literature review risk patterns specialist areas social media security intelligence sources workshops corporate sus compliance sustainability elearning programmes class tainability committee risks assessed room training workshops place improve expert crossfunctional team resulting short list five standing risk help employees manage appropri business sustainability risks integrated ately group risk management process additionally established incident management teams five business sustainability risks identified throughout roche group ensure act quickly earthquake basel tokyo south san francisco emergency teams regularly rehearse different cri inadequate strategies cloud mhealth mobile devices sis scenarios alerts escalation procedures continue ehealth electronic devices social media strengthen business continuity management bcm cyber attacks ensure sites respond effectively catastrophic issue response yet optimised events deliver minimum acceptable level key products severe income disparity responsible business roche annual report safeguarding patient safety whether roche infringed legal obligations relating reporting adverse events infringement ensure every roche product effective safe procedure ongoing ema expected issue established systematic process designed opti report eu commission april mise patient safety throughout lifecycle medicine drug counterfeiting collaborate regulatory agencies monitor reports counterfeit medicines diagnostic products serious adverse events experienced patients communicate growing global problem counterfeits found product safety activities appropriate audience every disease category every region world medicine may cause side effects patients often look identical authentic versions difficult priority make sure therapeutic benefits detect particularly patients main concern patient medicine outweigh risks quality processes health safety substandard falsified drugs medicines systems regularly audited internally inspected mean difference life death patient regulatory authorities work closely relevant stakeholders including pro employees required immediately report issue fessional investigators international associations national relating safety quality medicines new learn authorities help identify withdraw counterfeit medical ing solution put place training reporting products market support prosecution adverse events end year required criminals involved addition train local officials employees completed training involved public education counterfeit medicine adverse events stored global database reviewed along pharmaceutical companies qualified physician reported promptly appropriate entered agreement interpols pharmaceutical regulatory authorities required link roche crime programme build work medical product evaluate whether benefits medicine still product counterfeiting pharmaceutical crime unit outweigh risks also maintain strict product recall programme include training capacity building targeted procedures ensure withdraw products rapidly enforcement actions build awareness issue well quality safety problems arise disrupt dismantle organised crime networks involved despite safeguards following internal quality review order effective comprehensive series anticoun end roche identified unreported potential terfeit measures needs place including harmonised missed adverse events patient assistance program product serialisation universal use safety features united states collaboration relevant health goal prevent people harmed counterfeit authorities retrospective global search conducted medicinal products internally implemented internal identify unreported adverse event reports com technical anticounterfeiting measures design pack pleted safety assessment impacted product aging labelling products also continue work authorities system track trace products november european medicines agency ema distribution dispensary announced prac pharmacovigilance risk assess ment committee confirmed roche assessment addition initiatives strengthened medicines based available safety information con internal structure network experts worldwide firmed benefitrisk balance medicines share knowledge coordinate response counter impacted medicines remain authorised without feit cases involving roche products allows us immedi changes treatment advice patients healthcare ately inform relevant health authorities potentially professionals corrective preventative actions resulting counterfeit products brought attention action health authority inspections took place early plan ensures rapid detection analysis suspect products implemented timely coordination reporting authorities parallel reinspection authorities november resulted additional findings roche ad dressing ema also initiated procedure investigate roche annual report responsible businessbiosimilars biosimilars exact copies innovator biological product unlike generics chemically synthesised medicines structural complexity products well uniqueness biological production process means biosimilars never identical original medi cines presents new challenges regulators pharmaceutical industry first ever bio similar monoclonal antibody approved europe non roche medicine discussions underway world biosimilar regulation place health organization agree new convention naming biosimilar regulation development reflects nonidentical nature active sub data stances produced independently developed manufacturing processes cesses following guidance issued world health view biosimilars must meet rigorous regulatory organization could safety efficacy implica quality standards comparable original medicines tions patients end roche working regulators providing knowledge order approval standards appropriately set overall confident strategy innovate expand protect ensure stay ahead biosimilars competi regulatory environment develops globally bio simi tion example launched number new stand lars raised concerns differing standards reg ards care cancer including subcutaneous version ulation emerging markets example approval pro herceptin well kadcyla perjeta gazyva human rights well roche group employment policy policy safety security health environmental protection roche fully supports implements protect respect policies rigorously enforced internally externally remedy approach un human rights councils ruggie framework equally committed complying un global compact principles universal declaration human rights fundamental labour rights stipulated international labour organizations declaration fun damental principles rights work consistent global standards across areas company support respect human rights within sphere influence human rights embedded code conduct actively ensure roche com plicit human rights abuses commitments detailed code conduct supplier code conduct responsible business roche annual report helping establish private health insurance cancer roche annual report making innovation accessiblechina number policies sold covering cancer treatment cancer killer urban areas china second leading cause death china whole full course cancer medicines cost times average chinese workers annual income working insurers develop coverage cancer chinese population health insurance policy covers cost cancer treatment roche teamed ten local insurance companies including three largest help develop additional policies cover cancer treatment care seminars client forums cancer awareness campaigns run roche helping educate insurers wider population cancer treated making innovation accessible roche annual report employees worldwide roche annual report people reached top quartile best employers employees engaged launched global wellbeing week activities roche sites reached goal women key positions year ahead schedule roche annual report people key figures women key positions since reaching goal year early roche employees worldwide fulltime equivalentsfte employees fte function europe marketing distribution north america research development asia manufacturing logistics latin america servicing australia general administration africa total total employees fte operating unit employees contract type roche pharmaceuticals regular fte chugai fixed term fte diagnostics division full time headcount part time headcount total fulltime equivalent fte used reflect actual working time full parttime employees example two parttime employees working would result equivalent one fte versus two employees headcount number ftes increased primarily result growth pharmaceuticals business asiapacific introduction full potential people fundamental inno vationdriven culture purpose roche believe every employee make mark patients need next make difference hire outstanding people help manage careers recognise reward excellent work also aim provide people managers priorities great leaders things whilst embracing diversity inclusion living values integrity performance courage passion together activities create great place work strategic priorities focused five key areas every person feels valued respected grow engagement diversity inclusion leadership talent attraction retention roche defines key positions top positions corporate operating group level key positions performance roche annual report peoplepriority aim performance engagement global achieve employee engagement employee engagement score percentage points employee levels globally end exceeding industry benchmark reaching survey top quartile best employers health foster culture health launched global wellbeing week activities sites wellbeing wellb eing worldwide diversity inclusion diverse key positions end key positions held women inclusive held women succession pipelines key positions women workplace promote diversity inclusion nationalities represented international assignments tolerance discriminative behaviour international assignees women offer flexible benefits working attendees global leadership programmes women arrangements meet diverse roche employees satisfied benefits exceeding needs employees industry benchmark benefits close best employer benchmark roche affiliates offered flexible benefits elder care new benefit programmes piloted basel sites roche affiliates offered flexible working hours offered parttime working arrangements offered working home leadership great leaders shape common global leadership roche leadership commitments performance expectations culture unique roche communicated across organisation integrated relevant hr practices development planning programmes tools including degree feedback talent management performance management talent attraction retention attracting ensure robust pool qualified internal key position vacancies filled internally retaining candidates critical positions international assignments emerging markets best talent build pipeline key external talent career development portal job boards launched globally aligned business needs using increase training hours per employee compared latest technology methods develop employees levels performance driven culture creating foster culture continuous employees reported performance feedback performance performance feedback dialogue line managers improved since new compensation driven culture embed new globally aligned performance management principles introduced compensation performance employees managers felt changing management principles principles right thing respond geos survey employees managed measurable targets based indicated employee recognition could multidimensional performance appraisals improved pilots rollout plans applause global recognition programme completed place globally january range optimal employee engagement levels corporation begins benchmark best employer according methodology aon hewitt global hr consultancy source aon hewitt source hr benefits hb diversity internal survey total roche affiliates participated survey people roche annual report engagement employees geographic region people drive business understanding matters europe people makes working roche rewarding australia engaging experience critical success well people africa latin america measure employee engagement primarily global employee opinion survey geos objective asia end reach employee engagement level north america global benchmark best employers across industries made good progress towards goal since first survey employer choice recent survey placed employee engagement roche consistently recognised employer significant increase choice employees external institutions publi putting us ahead industry global benchmarks cations recognition reflects efforts create strong optimal employee engagement employer brand differentiates roche competition attests commitment help employees build careers since first survey taken feedback collaborative work environment seriously initiating activities either address shortcomings ensure maintain positive features example health wellbeing work groupwide improvement global initiative live well find balance launched percentage employees felt valued listened september first wellbeing week sites senior leaders also seen percentage point worldwide participated programme aims fos improvement employee perception career opportunities ter culture health wellbeing amongst roche employ another clear indication progress rate ees promote worklife balance employee participation compared continues give us clear understanding programme focuses four themes healthy lifestyles pre employees think feel working roche vention practices emotional wellbeing resources avail able roche many sites also offer range health conduct next engagement survey september wellbeing information activities services throughout year include employee assistance programmes health checks including vaccinations immunisations fitness nutrition programmes stress management interna global employee opinion survey geos tional sos assistance results diversity embracing diversity enrich every decision discussion roche bring innovative solutions business facets diversity important us gender race culture also diversity thought participation engagement experience believe creativity decisionmaking problemsolv ing driven ultimately made better different range optimal employee engagement levels corporation sometimes conflicting approaches perspectives experi begins benchmark best employer according methodology aonhewitt global hr consultancy roche annual report peopleworldwide recognition roche award roche site fortune best companies work roche diagnostics indianapolis fortune best companies work genentech crf institute top employer china roche diagnostics china crf institute top employer switzerland roche switzerland crf institute top employer uk roche uk star employer germany praktikantenspiegel roche pharma germany great place work greece roche hellas great place work denmark roche denmark great place work colombia roche colombia desired employers roche diagnostics poland science top employer genentech roche russia best employer aon hewitt roche russia lithuania best employer aon hewitt roche lithuania slovakia best employer aon hewitt roche slovakia romania best employer aon hewitt roche romania ences promote inclusive environment individu also provide targeted development opportunities includ als exchange ideas opinions openly respectfully ing mentoring sponsorship programmes participation leadership networks example regularly sponsor today employees women worldwide women science women leadership forums employees represent different nationalities larger sites basel south san francisco indianapolis represented headquarters site basel mannheim gender diversity supporting diversity encourage diversity work take flexible approach benefits matching local programmes varied needs women total workforce employees across world benefits include sabbaticals women line management parental leave familyfriendly services eg child care sick women key positions child leave flexible working arrangements also support gender diversity executive committee effort help employees balance gender diversity continues top priority goal work personal commitments line country women least key positions sitespecific regulations accommodate company already reached goal women offers possible flexible working hours including part key positions compared time job sharing opportunities flexible work location arrangements working home shared desk working ensure women fully represented open plan offices pipeline internal candidates key positions increased percentage women pipelines global employee survey showed employ also increased number women identified ees satisfied benefits percentage points high potentials internal talent pools benchmark pharma companies line international assignees also women overall best employers percentage women hired roche managerial level increased end women continued improve benefit programmes held management roles sites basel united states initiated pilot programmes people roche annual report policies address needs growing number development employees eldercare responsibilities leadership development remained top priority roche emphasis people leadership embed equal opportunity ding leadership commitments within organisation roche equal opportunity employer tolerate commitments introduced sites integrated workplace discrimination kind take action case relevant hr development practices globally misconduct additionally respect employees right freedom association collective bargaining senior leadership programmes catalyst also support embedding commitments programme aims improve individual collective leadership skills senior leaders within context adapting business leadership organisational change end target audience senior leaders participated programme believe every roche employee deserves great leader corporate executive committee members helping facil someone inspires engages team every inter itate session action provides employees opportuni ties continuously discover learn develop contribute also launched leading leaders roche programme globally programme targets midlevel sentiment captured leadership commitments leaders helping apply leadership commitments developed input authentically conducted two pilots five pro senior leaders response geos commitments grammes fullscale rollout planned provide baseline leadership development programmes capture promise employees expect leaders challenging conventional participants receive candid feedback london business thinking school adviser roche executives attendance course module horizons programme gives leaders high potential employees participated horizons programme opportunity challenge conventional thinking experi ence excitement launching new concept participants learn take personal responsibility innovation change inspire others leader create environment innovation flourish working teams leaders challenged expand hori zons beyond immediate area responsibility eveloping testing hypotheses response critical business chal lenge programme aims improve expertise leaders six months areas strategy management innovation change roche annual report peopledegree feedback media linkedin twitter facebook youtube another important element leadership development pro generate interest careers working roche grammes global degree feedback tool encom passes behaviours core competencies asso ciated attracting employees leadership commitments helps leaders assess individual strengths development targets global norms new hires internal staffing rate external staffing rate talent attraction retention retaining employees turnover talent strategy pursue recruitment excellence total implement strategy attracting outstanding highly europe skilled motivated people helping perform consist north america ently high levels focus retaining employees asia cycle regular development recognition rewards tied latin america performance additionally seek continuous supply australia diverse talent qualified help us innovate deliver africa business objectives recruitment reasons leaving job vacancies filled internally work continuously identify develop pipeline em ployee candidates key positions also focus building employeeinitiated external talent pipelines fill gaps internal talent pool employerinitiated meet succession management needs strong neutral employer brand improves ability attract quality external candidates whilst reducing time hire cost exter nal recruiting agencies career development roche aim provide work environment face stiff competition top talent science medi employees encouraged build careers pursue cine especially emerging markets india china passions believe career development partnership developed markets like san francisco bay area employees managers employees united states responding challenge driving careers role provide right resources global approach includes inhouse recruiting teams including broad range activities experiences roles talent scouts search potential candidates key posi promote learning growth opportunities tions filled internally recruited senior employees external sources key positions communicated career development philoso phy launched career development websites globally continue attract hire top talent using traditional specifically pharmaceuticals sites along recruitment practices job postings referral pro development activities provide employees resources grammes recruitment university business schools manage careers resources also help career websites countries drew million visits employees assess personal interests strengths compared million received well identify development needs specific career options applications posted vacancies registered new outlined websites encourage employees candidates database job seekers interested becom think potential moves including lateral cross ing roche employees also expanded use social functional opportunities well stretch assignments aim continuous learning people roche annual report training hours per employee achievements due commitment senior leaders regular talent reviews supported global roll succession modules chris global hr information solution leadership pipeline number highpotentials percentage women highpotentials additionally employees contractors world percentage women wide used online learning solution tool lso com global leadership pleted courses training including specifically related programmes compliance daily average employees attend instructorled event webbased courses com pleted performance learning development roche strive performancedriven culture performance management process support continu total training investment ous dialogue feedback aims develop people million chf rewarding performance maximising business results training spend per employee chf since maintained globally aligned performance total number training hours management principles also reflected approach million compensation matter employees work average training hours recognised rewarded innovation performance per employee teamwork demonstration roche values core number postgraduates competencies interns benefits approach evident pulse check excluding chugai survey completed may employees reported performance feedback line managers improved since believe activities contributing factors new compensation performance management princi percentage point increase employee engagement scores ples introduced addition employees career opportunities managers felt change right thing multidimensional performance appraisal process includes succession management access online multiinput feedback tool helps maintain specific succession plans key collect feedback performance variety sources positions monitor plans continuously ensure strong diverse pipeline talented candidates recognition recognising employees time effort helps us result key position vacancies filled retain engage people ensure people feel internal candidates close came valued succession plans many roche sites recognition programmes place end also maintained succession plans within ever fully support increasing number broader organisation positions repre global crossfunctional project teams address gap senting increase number plans maintained piloted applause recognition programme continue strengthen strategic priority employees south san francisco united states roche annual report peopleremuneration roche connect employee programme purchase roche chf billions securities discount showed steady progress elev enth year participants additionally managers employees received award roche long term incentive lti plan lti plan provided partially form restricted stock units rsus year vesting period thereby offering lti recipients competitive package better aligned value equity held roche shareholders global product development function plan launch applause across sites january online pro gramme better supports geographically diverse teams improves consistency transparency recognition encourages frequent feedback employee employee anywhere within roche compensation compensation reinforces culture performance plays key role attracting motivating retaining top talent compensation principles focus value creation success shar ing fairness transparency balancing long short term remuneration affordability market competitive ness spent billion swiss francs remuneration compen sation benefits also saw greater differentia tion reward payments reflecting efforts integrate payforperformance principles differentiated rewards throughout organisation efforts helped establish common language tools performance appraisals compensation reviews across organisation improvements compensation performance management also facilitated online platform chris used affiliates le cercle sirh french association hr information system professionals granted chris team hr information system strategy award collaborative solution harmonises hr pro cesses improves hr management worldwide people roche annual report supporting healthcare system treat cancer roche business report making innovation accessibleperu increase cancer coverage plan esperanza plan hope population cancer coverage plan hope plan hope private militarysocial security public health system sis working government first public cancer coverage poor recently public healthcare funding cancer treatment unattainable majority peruvians new government national oncology plan known plan esperanza plan hope set address provide access treatment common cancers first time cancer care available general population since roche peru supporting plan educational cancer awareness campaigns strengthening diagnostic testing well helping establish healthcare facilities assisting medicine pricing making innovation accessible roche annual report employees walked childrens walk since roche annual report community involvement marked years supporting children need donated supplies victims typhoon haiyan launched roche young commissions young composers roche annual report community involvement key figures breakdown contributions humanitarian social projects science education area arts culture community involvement roche employees engage variety community global activities guided roches philanthropic dona philanthropic projects enthusiasm idealism tions noncommercial sponsorship policy philanthropic bring discovery development new medicines donations may made registered accredited inde diagnostic products carries involvement social pendent nongovernmental organisations multilateral organi educational humanitarian cultural causes aim sations notforprofit charities active longterm partner entering projects early stage sharing project investments risks employee involvement focus resources selected projects make lasting impact contributions directed four distinct areas humanitarian social projects community envi roche continued enable employees con ronment science education arts culture empha tribute skills expertise healthrelated challenges sis placed projects reflect following criteria worlds poorest countries roche support innovation provide creative effective solutions employees spend three twelve months working targeted problem developing country partner organisation sustainability deliver enduring results dynamic expertise area since roche employees sourceconstrained world temporarily assigned projects countries india collaboration complement work partner organisa haiti kenya tanzania ghana ethiopia niger swaziland tions resources skills togo outcomes generate tangible longterm benefits people communities involved decade dedication childrens walk celebrated th anniversary since employees basel nutley palo alto sites joined walk number participants grown steadily reaching employees sites funds raised matched roche roche annual report community involvementhumanitarian engagement malawi social projects marks th year involvement malawi start collaborated european coalition positive believe improving services support systems people provide hivaids orphans food education one effective ways build stronger healthier skills training participation quickly expanded include communities developing countries investment education roche employees worldwide annual roche childrens basic health awareness plays major role building walk fundraising event helps vulnerable children every foundation community sustainably however majority funds directed long term projects malawi held june coincide south africa roche sponsors transnetphelophepa ser day african child vice brings healthcare education remote communi ties throughout country collaboration transnet addition roche partnering unicef build teach foundation philanthropic arm south africas largest ers training college malawi train many teachers stateowned transportation company roche funds mobile possible help reduce number students per teacher healthcare clinic known locals miracle train includes building classrooms providing learning service actually two car trains deliver medical ser terials adds previous projects conducted unicef vices healthcare education people malawi support schools systematic way annually including patients need care transnetphelophepa staff also visit schools providing primary health checks medicines education phelophepa means good clean health local dialects good neighbour activities described children participate educational programme brazil programme promote integration young people working environment regular prevention campaigns topics hepatitis breast cancer diabetes brazil roche expanded efforts support children families taken part pro programa vizinho legal good neighbour programme grammes teenagers become members theatre community jaguar paulo started group performs many cities across country jaguar shanty town close roche affiliate paolo characterised high unemployment related social problems including high rate teenage pregnancy initially roche employees offered music sports courses children school hours activities included violin guitar drum lessons english courses theatre dance groups well soccer programme vizinho legal became official rochesponsored programme subsequently expanded include schools companies healthcare institutions religious school con gregation joined also provides rooms used classes parent meetings presentations events apart community involvement roche annual report parallel roche philippines consulted local authorities assess identify short longterm needs including ways roche contribute philippines recovery recognising young employees local affiliate also contributed starting scientists fundraising campaign liaising local red cross money raised bought blankets personal hygiene objects packed delivered roche hong kong launched young scientist red cross distribution roche made separate financial award encourage students aged demonstrate donations several employees c uriosity passion science developing innovative approaches improving peoples quality life winning proposal submitted three talented yearold hong kong community environment students tactile handwriting word learning kit dyslexic students kit removable sandpaper mesh sheet placed smart phone tablet computer screen responsibility majority philanthropic activities enable dyslexic students feel see letters lies roche local affiliates operate coun tries every roche affiliate projects support local communities approach aim tailor activities effec tively local needs united states example genentech gives back week thousands employees donated money food time nonprofit organisations result real positive change communities participation volunteer projects donations educational supplies clothing food activities science education business founded excellence innovation science seek increase public understanding life sciences inspire future scientists end support programmes natural disaster support enhance science education draw talented students science careers engage outstanding young scientists roche disaster response model guides contributions teachers communities experienced unprecedented natural disasters local offices able offer immediate roche active supporter swiss youth science response emergency phase disaster long foundation raises awareness appreciation science term support reflects global focus providing sustainable among young people national competitions study assistance help affected communities get back feet weeks also support swiss talent forum politically independent think tank young adults get together typhoon haiyan one strongest storms record experts highprofile personalities business science resulted unprecedented natural disaster medical society politics discuss potential solutions global crisis philippines response roche donated supplies challenges time two highly effective antibiotics bactrim rocephin using local stock speed delivery need medicines provided phapcares foundation roche annual report community involvementarts culture across europe opportunity participate programme activities explore themes creativity innovation roche supports contemporary art cultural projects synergies arts science students spend actively cultivates artistic talent focus innovative art week salzburg austria participating creative workshops music creative activities express science artistically attending selected contemporary classical concerts fea explore interaction art science tured salzburg festival programme roche launched roche continents partnership salzburg festival year roche offers students supporting composers director lucerne festival partner roche commis sions commissioned work premiered lucerne samy moussa montreal canada piotr festival summer peszat krakow poland first composers receive roche young commissions compose orchestral works guidance pierre boulez lucerne festival academy programme extension roche commissions pioneering collaboration established roche lucerne festival support contemporary composers innovation arts culture roche commissions offers contemporary music artists challenge opportunity forge new frontiers field started every second year recognised contemporary composer selected recommendation artistic community involvement roche annual report supporting people diabetes roche business report making innovation accessiblepakistan cases diabetes pakistan growing dramatically increased awareness changes lifestyle exercise nutrition help people better manage diabetes complications broader access information monitoring tools healthier lives roche provides awareness guidance locally best manage diabetes avoid complications countrywide education programme support doctors paramedic staff nurses experts advise people live condition sessions clinics hospital wards programmes run every month since inception making innovation accessible roche annual report percent reduction roche accident rate roche annual report safety security health environment decreased greenhouse gas emissions per employee reduced heavy metals discharged water ways increased share sustainable energy roche annual report safety security health environment key figures energy intensity gjemployee co intensity temployee total environmental impact million impact pointsemployee roche accident rate rar daysemployee includes firsttime phosphorus reporting phosphorus emissions based amount phosphoric acid used site genentech production sites roche safety security health environmental protection believe education awareness training best integral part operations ways foster employee engagement responsibility approach level commitment mind conduct regular training sessions businessrelated activities strive continuous regional conferences workshops provide online tools improvement wherever possible economically viable local languages employees employees par monitoring performance regularly ensure compliance ticipated approximately hours training standards objectives well ensuring behaviour processes equipment stateoftheart audits assessments prevention however key effective management policy internally audit critical sites chemical devote special attention main tool pro pharmaceutical diagnostic manufacturing facilities every fessional risk management three years relevant sites periodically according risk audits assess performance internal standards stipulate future improvements plant manage ment local officers conduct frequent checks improving monitoring inspections assess compliance standards performance expect contract manufacturers suppliers service providers meet standards ensure employ people worldwide expert teams compliance thirdparty auditors retained us period roche site identify risks develop mitigation plans ically inspect operations suppliers issue recom communicate policy guidelines employees mendations improvement event noncompliance stakeholders motivate implement nec may either terminate contract refuse renew essary measures audits effectiveness management system reviewed frequently employees encouraged identify areas improvement recommend changes required using internal audits database best practices employees frequently followup share knowledge exchange new ideas topics first time proposals database adopted external audit areas within organisation followup first time coverage key figure aimed least roche annual report safety security health environmentin followed earlier audits confirmed accidents per employee per year rir corresponds improvements made interim period recom number working days lost due occupational diseases per mended improvements following audits included employee per year increasing involvement line management training level managers improving risk analysis approach aim minimise employee working days lost due occupational accidents illnesses actively support employee health safety set realistic goals materiality projects aimed keeping accidents minimum therefore established health safety committees virtually roche assess material issues roche sites engaged technical activities produc significant positive negative impact company tion laboratories workshops warehouses many materiality issue influenced external inter sites according risk levels nal factors example external regulations laws may affect strategy stakeholder expectations industry maintain integrated programme employee consulta reporting conventions considered factors tion workplace inspections training across business including ability influence issue identifying areas approach promote strong safety culture importance relevance matters included empowers employees report address safety reporting managed actively goals within areas roche analysis indicated important areas employee health safety resource efficiency environment dont dummy protection technical assets looked main material issues slogan dont dummy basel site initiated considered potential future developments analysed need local information campaign raise awareness group feasibility act defined performance indicators initiated occupational accident goal subject accidents projects set goals based strategy following general featured yellow crashtest dummy symbolic indicators set priority material issues figure potential accident victim sixmonth period covered chapter team members highlighted typical situations dummys occupational accidents occupational diseases behaviour could lead avoidable accident teams energy management air emissions message consciously avoid accidents modifying water management use behaviour campaign targeted employees security including supervisors ensure employees able pharmaceuticals environment work optimal health safe conditions occupational accidents occupational diseases employee absenteeism due occupational accidents occupational diseases including unhealthy stress neg ative impact company providing safe healthy workplace employees therefore priority p rimary objectives keep roche accident rate rar reducing reduce roche illness rate rir less rar corre sponds number working days lost due occupational safety security health environment roche annual report issues expect similarly rigorous policies contrac frequency compared resultant number days tors safety employees outside business hours lost however increased overall also important therefore sell discounted protective equip due increase worked hours rar went ment recreational activities well sport equipment rar low level therefore single accidents resulting longer absence result performance fluctuations due negative trend occupational accidents past two years intensified accident prevention activities number reported cases occupational illnesses de roche accident rate rar showed significant creased furthermore related working days decrease workrelated accidents decrease lost declined reduced overall roche illness rate lower occupational accident illness profile remains con sistent slips falls repetitive strains representing majority workrelated incidents sincerely regret roche turkey reducing employee died road traffic accident italy burden environment carrying duties employee safety health roche turkey certified world wildlife funds green office programme employees actively took basis steps reduce workplace environmental footprint roche accident rate first certification pharmaceutical company turkey roche illness rate number total actions taken achieve green office certi workrelated fication including following accidents optimising staff shuttle bus routes reduce driving distance cases avoid kilogrammes carbon emis workrelated sions year illnesses reducing office paper use saving sheets workrelated year fatalities eliminating use paper cups annually purchas workrelated ing mugs accidents removing water dispensers per million installing light switches prevent unnecessary lighting working hours planting seedlings roche forest esme resource efficiency environment commitment using natural resources sustainable manner fundamental roches environmental strategy research manufac ture pharmaceutical diagnostic products dependent natural resources raw materials fuel water consequently roche fully aware corporate responsi bility sustainable future committed using natural resources efficiently company decreases environmental footprint turn benefits stake roche annual report safety security health environmentholders society reducing greenhouse gas emissions ecobalance environmental health problems roche also numbers impact points see text benefits economically using green technologies ser vices transitioning sustainable energy recycling reduces costs eg energy raw materials improves growth competitiveness creates employment oppor tunities thus aiding society additionally less roche depends nonrenewable resources less vulnerable primary energy supply constraints volatile market prices roche generate highvalue products relatively low levels energy used operations total raw material emissions air energy use per million swiss francs products sold terajoules compares well pharma ceutical companies chemical industries also applies relatively low co emissions part commitment sustainable development proactively seek employ new sustainable technolo water gies processes minimise environmental impact ecobalance established groupwide goal ecobalance levels allows local site management freedom develop locally appropriate strategies objectives reducing environmental impact landfilled waste emissions water ecobalance refers consumption energy resources emissions waste business activities describes total environmental impact environmental impact per operations allocating environmental impact points employee million impact points roche products ecologically relevant parameters consumption natural resources emissions air water soil obtain view demand place earths eco systems points added related raw material efficiency kg raw materials used per kg total number employees enables us monitor products produced improved environmental impact per employee million impact points ecoefficiency rate total environmental impact per employee slightly decreased ecoefficiency aims minimise ecological damage whilst decrease might maximising production efficiency using less energy materi greater two big biotech production sites vacaville als water decreasing hazardous emissions products oceanside united states reporting full phos increasing recycling use ecoefficiency rate eer phorus emissions either first time based total measure monitor performance eer ratio amount phosphoric acid used site following period sales expenditure environmental protection environ shutdown mental impact points using formula sales expenditures impact points calculated accordance swiss improvements decreasing amount landfilled federal office environment example eer improves waste slight decrease volume withdrawn water increases sales increase expenditures environ increase head count positive effect environ mental protection remain constant environmental harm mental impact total use raw material increased reduced safety security health environment roche annual report efficient cooling approximately litres fuel oil equivalents carbon emissionfree heating dioxide reduction around tonnes per year data centre efficiently cooled time nearby buildings resourceefficiently heated end heat pump kw heat output installed roches kaiseraugst switzerland site removes waste heat computer centre uses heat water temperature c thus providing heating eight office buildings laboratory building technology provides necessary heating buildings housing approximately employees represents saving energy management ecoefficiency rate eer roche committed minimising environmental footprint sales meaningful ways contributing sustainable energy million chf future transform vision reality set energy environmental saving action plans sites include implementa expenditure tion innovative technologies continuous upgrading million chf infrastructure improve energy efficiency purchase ener environmental gyefficient equipment including hybrid diesel efficient impact cars review employees travel needs also change environmental work processes complex task highly regulated impact points approved facilities focusing effects eer x steady transition use sustainable energy today approximately energy used roche comes seek improve eer primarily reducing material fossil fuels nonrenewable depleting sources energy consumption well waste using renewable coal oil natural gas result produce green resources eer decreased primarily due house gases mainly carbon dioxide waste products increase environmental spending increase contribute climate change air pollution environmental impact points aim use energy efficiently possible reducing addition spending million swiss francs environ energy consumption possible increasing use mental purposes investments operating cost sustainable energy continuing expand global safety security amounted million swiss francs business hence total spending measures approximately million swiss francs compared energy intensity consumption million swiss francs included increase roche actively reducing energy intensity measured roche increase personnel well increase energy per employee well increasingly using energy security measures medical services replacement sustainable sources meet energy requirements wastewater treatment plant energy conservation benefits environment avoiding air pollution reducing greenhouse gas emissions bene roche annual report safety security health environmentfits roche lowering costs increasing reputational value energy use terajoules efficient use energy also ensures business continuity sustainable future generations come goal twofold first aim reduce energy intensity gigajoules total energy gj per employee levels total energy expect reduce energy consumption per employee per million chf approximately baseline levels second sales plan increase proportion sustainable energy used total energy total energy consumed per employee despite strong sales growth managed ensure use resources low possible share sustainable energy increase energy used buildings stationary actual data goal equipment gas fuel oil waste electricity increase car fuel consumption increase sustainable energy use bringing total sustainable energy consumption reduction efforts business travel less successful energy consumption air travel increased comprising total energy number initiatives field compensate negative nonsustainable sustainable impact globalisation together increase number employees air emissions resulted overall improvement energy intensity priorities avoid air pollutants reduce quantities gj per employee absolute energy pollutants control remaining pollutant air emissions line consumption increased energy consumption ecobalance goals overall objective keep gj per employee surpassed goal target emissions air low levels achieved gj per employee recent years way resource management improved emissions strategy prescribes continuous improvement demonstrated genentech site san francisco manufacturing sites includes using flue gas scrub usa site participating us green building coun bers reduce nitrogen oxides sulphur dioxide vari cils best buildings challenge committing reduce energy ous incineration freezing processes reduce release water waste per employee buildings volatile organic compounds vocs may also reduce years taking buildings together site already energy use halfway point challenge emissions air roche sites low levels energy use type means new processes activities well timing sampling result fluctuations seen natural gas emissions air tonnes grid electricity district heating vocs air travel particulates waste nitrogen oxides sulphur dioxide oil car fleet safety security health environment roche annual report greenhouse gas emissions recent acquisitions lack alternatives coun greenhouse gas ghg emissions roche originate tries make complete elimination halogenated refrigerants transformation use energy goal improving unrealistic nevertheless continue examine alter energy efficiency therefore also applies ghg emissions natives work refrigeration suppliers make reduction measured tonnes per employee reductions aim reduce halogenated refrigerants levels expect achieve reductions legacy roche sites substituting fossil fuels energy sustainable sources recently acquired companies genentech ventana cut ghg emissions tonnes halogenated hydrocarbons tonnes per employee implementing energysaving measures reduced amount fuel use heat cool operate sites inventory emissions greenhouse gas emissions co equivalent total emissions water management million tonnes total emissions per million chf business dependent reliable supplies highquality sales tonnes water almost chemical biotech pharmaceutical diag nostics manufacturing processes involve water reagent solvent cleaning cooling agent pharmaceutical transportation also contributor emissions industry globally poor quality water resulting higher costs logistics service providers lsps reduce co footprint purification greater risk product contamination transportation need know overall emissions also use water energy carrier refrigeration heating terms carbon accounting system provide data installations basis required manage emissions developed soft warebased tool calculate intercompany approach direct delivery shipments uses one standard ensure effective water management roche sites either lsps certified bureau veritas compliant working implementing programmes reduce water eu iso standard requirements consumption recycle reuse water view water supply use best managed monitored locally shipments modes transportation assessed reason sites set local targets set group single shipment basis allows us identify emissions wide water quantity targets drivers focus methods emission reduction however support global efforts promote water another initiative reduce greenhouse gas emissions protection conservation improve access clean roche reduce use halogenated refrigerants drinking water longterm commitment reduce water used cooling equipment remain atmo consumption reflected goal improve total eco sphere long period time since made balance compared baseline fur significant progress reducing emissions halogenated hydro thermore aim reduce total waste water toxicity carbons eliminating halons reducing fully halogenated baseline meantime continue compounds except us genentech ventana investigate reliable performance indicators measurement sites came later reduction programmes methods establishing waste water toxicity baseline later target dates half water draw used cooling circuits even though water chemically contaminated analyse discharged rest purified treat ment plants released waterways roche annual report safety security health environmentwater traps hillsboro site oregon usa estimate planned water project save approximately cubic metres water annually reduce water consumption land scaping soil containing crystals consist super absorbent polymer water crystals trap moisture releasing soil required crystals planted new vegetation tilled planting beds reduce run irrigation rainfall turn overall cost irrigation performance transferred million cubic metres waste water record organic emissions water total organic car treatment plants resulting discharge tonnes bon processing waste water treatment plant organic matter small increase compares favourably discharge waste waters pollutants comply fully growth seen addition discharged kilo relevant regulations including pretreatment requirements grammes heavy metals leaching metal pipes operations waterways approximately elimination rates waste water treatment plants already high seek minimise water water everywhere contamination water roche committed part help protect reducing discharges toxic poorly biodegradable conserve water roche offices many parts world substances heavy metals quality water could still issue therefore reducing generation waste water becomes important ensure employees provided treating pretreating waste water ozone access clean drinking water cases non poorly degradable contaminants roche became signatory wash pledge water use discharge access safe water sanitation hygiene implementation workplace movement started ensure appropriate access safe water sanitation water withdrawn hygiene employees premises signatory million companys control water used million waste water discharged pledge started genevabased world business treatment plant council sustainable development providing facilities million leads healthier productive employees organic matter discharged waterways treat ment tonnes heavy metals discharged waterways treat ment kilogrammes safety security health environment roche annual report waste management security accept responsibility waste generated oper protecting employees physical assets critical infor ations including previously deposited sites mation integrity brands products prin landfills permit landfilling last resort even cipal concerns roche preventative measures priority inert materials slag incineration ash aspects security depending availability suitable local waste treatment plants may dispose nonhazardous general waste information security awareness campaign r em authorised landfills ployees started completed r departments roche group specialist team consisting performance members global departments security competitive waste parameter ecobalance intelligence legal briefed total employees waste reduction targets reflected goal improve eight different roche sites individual sig groups ecobalance compared nificantly mitigate risk theft loss businesscritical establish waste reduction goals individual sites however information set groupwide goal primarily large yeartoyear fluctuations waste construction security activity included launch global demolition activities logistics security programme pharmaceuticals division goal systematically improve protection production pharmaceutical diagnostic prod products theft manipulation transportation ucts supported strong growth roche chemical storage thirdparty warehouses small team led waste increased general waste decreased global pharma supply chain comprising security experts different sites elaborated global guideline tools evaluate mitigate risks well report incidents former user kesslergrube landfill grenzach respect programme rolled roche wyhlen germany roche started remediation project sites roche affected criminal attacks product also evaluating various remedial options former transports well hot spots include latin american countries production site belleville new jersey usa extensive italy fourphase remediation project underway site nutley new jersey usa scheduled completion third security focus set north ameri end security workshop held south san francisco united states site security officers us canadian sites waste produced tonnes discussed challenges good practice three key topics region workplace violence logistics security phys ical site protection general waste general waste per million chf sales chemical waste chemical waste per million chf sales roche annual report safety security health environmentpharmaceuticals pharmaceuticals environment environment roche acting concerns impact pharmaceu ticals environment considering entire lifecycle pharmaceutical plant patient drugs two goals safeguard ecosystem protect business potential longterm finan cial reputational risks traces pharmaceutical products enter environment variety ways including manufacturing process waste water treatment plant improper disposal unused medicines natural process following normal patient use patient use however inappropriate generally recognised primary contributor excretions disposal patients evidence suggests exposure resulting trace concentrations surface ground drinking water pose harm human health risks aquatic life thought greater scientific studies identified shortterm effects exposure lowlevel concentrations pharmaceuticals research conducted public waste water waste treatment plant evaluate potential longterm impacts production minimise release pharmaceuti cals environment designing manufacturing sites reduce risk active ingredients entering waste water products distributed support programmes collect expired medicines employ pro natural water system landfill active measures prevent release products environment include offering financial incentives ensure unused dated products returned retailers others supply chain establishing policies require returned waste pharma drinking water treatment ceutical products incinerated rather disposed landfills providing environmental risk assessments authorities new medicines drinking water pharmaceutical residues environment come three sources minor extent estimated emissions production site slightly larger part inadequate disposal unused medicines excretion patients httpenviroadvisorycom pdfpharmaceuticalsintheenvironmentaesgppdf safety security health environment roche annual report making sure everyone access medicines roche business report making innovation accessibleunited states key facts united states universal healthcare system estimate million people united states uninsured since first product approved genentech donated usd billion worth free medicine patients uninsured denied coverage giving uninsured access medicines need genentech access care foundation gatcf established help patients uninsured denied coverage receive genentech medicines free charge patients must meet certain financial medical criteria year gatcf provides support around patients united states making innovation accessible roche annual report foundation years ago roche years specialised leader researchfocused healthcare combined strengths pharmaceuticals diagnostics roche annual report corporate governance roche committed serving stakeholders basis successful implementation commitment stakeholders corporate governance principles accordingly put focus business activities sustainable value creation innovation prescribe management culture conforming recognised standards corporate governance policy transparent communication remuneration report roches success depends abilities dedication people recognition forms basis performanceoriented remuneration policy system roche annual report corporate governance corporate governance roche committed serving stakeholders basis companys articles incorporation bylaws successful implementation commitment curricula vitae members board directors corporate governance principles accordingly put focus corporate executive committee published business activities sustainable value creation inno website vation prescribe management culture conforming recognised standards corporate governance policy details please refer following report transparent communication strong board directors represents interests board directors shareholders stakeholders highly skilled managers act integrity extremely important th annual general meeting agm roche holding fifth consecutive year roche ltd march shareholders reelected pius baschera recognised dow jones sustainability indexes djsi paul bulcke william burns christoph franz deanne julius group leader sustainability within pharmaceuticals arthur levinson andreas oeri peter r voser beatrice biotechnology life sciences industry sustainability weder di mauro members board directors core business practices award reflects term two years provided articles incorporation commitment running business way ethical severin schwan elected new member board responsible creates longterm value stakeholders directors term two years provided articles incorporation corporate governance report sets structures processes rules roche takes basis well organising meeting immediately following agm functioning corporate governance roche com board directors determined structure compo plies relevant corporate governance requirements sition committees shown particular applicable laws swiss stock exchange six swiss exchange directives including commentaries forthcoming annual general meeting march thereto swiss code best practice corporate roche board directors propose christoph franz governance promulgated swiss business federation elected chairman board christoph franz thus economiesuisse companys internal governance frame nominated succeed franz b humer announced work particularly articles incorporation bylaws annual general meeting march would embodies principles needed ensure com standing reelection addition william burns panys businesses managed supervised manner decided retire member board directors consistent good corporate governance including necessary checks balances board directors thanks members long valuable contribution successful continuing develop printed annual report contains selected links ment roche roche website wwwrochecom readers thus provided snapshot company reporting date implementing ordinance excessive compensa also directed sources consult tion listed corporations verordnung gegen bermssige time uptodate information corporate governance vergtungen bei brsenkotierten aktiengesellschaften roche whereas annual report covers single financial vegv board directors shall propose annual year ending december website contains information general meeting scheduled march reelect permanent nature well latest roche news oneyear term members board directors standing election annual general meeting also elect chairman board directors members httpwwwrochecomaboutrochecorporategovernancehtm remuneration committee independent proxy roche annual report corporate governanceinformation relating board directors also resolved introduce execute first time occasion annual general meet corporate governance ing march votes remuneration well remote electronic ballot means authorisations instructions independent proxy become group structure shareholders mandatory submit annual general roches operating businesses organised two divi meeting resolution amendments sions pharmaceuticals diagnostics pharmaceuti articles incorporation required vegv cals division comprises two business segments roche pharmaceuticals chugai whereas genentech former third segment integrated roche phar maceuticals diagnostics division consists follow corporate executive ing four business areas diabetes care molecular diagnos committee tics professional diagnostics tissue diagnostics applied science business area dissolved end portfolio products integrated within diagnos effective april john c reed appointed head tics business areas roche pharma research early development pred business activities carried group subsidiaries member enlarged corporate executive committee associated companies detailed information roche reporting severin schwan holding ltd significant subsidiaries associated companies including company name listing information information member board directors includ domicile share capital equity interest listed ing years first election member finance report note roche group consolidated corporate execu tive committee listed pages financial statements subsidiaries associates board directors corporate executive committee major shareholders listed finance report notes roche group consolidated financial state ments equity attributable roche shareholders related parties pages note financial statements roche holding ltd significant shareholders andr hoffmann vicechairman board directors andreas oeri member board directors chairman boards corporate governance sustain ability committee serve respective capacities board committees representatives share holders group pooled voting rights receive remuneration set forth remuneration report finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive remuneration relationships exist shareholders pooled voting rights crossshareholdings corporate governance roche annual report capital structure board directors corporate executive committee information roches capital structure provided information member board directors finance report notes financial statements roche including years elected years holding ltd additional details contained terms end member articles incorporation roche holding ltd corporate executive committee listed pages changes equity detailed finance report notes curricula vitae current former members financial statements roche holding ltd last five years bodies information includ company share capital swiss ing information board memberships available francs divided fully paid bearer shares continuously updated internet nominal value swiss franc restric annual general meeting elects members tions exercise voting rights shares board directors staggered elections upon deposit shares voted without restrictions nominee voted separately see articles authorised conditional capital incorporation roche holding ltd minutes addition nonvoting equity securities nes th annual general meeting roche holding ltd held issued bearer form form part march starting members board share capital confer voting rights nes confers directors chairman members remunera rights one share participate available earn tion committee elected annual general ings liquidation proceeds following repayment meeting annual basis share capital roches nes rights pertaining exception franz b humer william burns thereto including provisions protecting interests arthur levinson severin schwan none mem nes holders described articles incorpo bers board directors member roches ration roche holding ltd corporate executive committee served executive information debt instruments issued capacity group subsidiary three financial outstanding bonds provided finance report years preceding current reporting period note roche group consolidated financial state internal organisation board directors ments debt division authority responsibilities board information employee stock options provided management remits board committees finance report note roche group consolidated information control mechanisms available financial statements equity compensation plans board dealings corporate management including detailed information stocksettled governed bylaws stock appreciation rights ssars plan roche board directors roche holding ltd organised restricted stock unit plan roche performance share ensure group conducts businesses respon plan roche connect roche option plan sibly focus longterm value creation roche issued options apart employee stock end roche board delegated certain responsibilities options provided finance report note several committees composition chairpersons roche group consolidated financial statements equity per december described com compensation plans options issued mittees authorities responsibilities defined detail connection debt instruments bylaws board directors neither options awarded employees debt instruments issued effect roches share capital httpwwwrochecomaboutrochemanagement boardofdirectorshtm httpwwwrochecomaboutrochemanagement executivecommitteehtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance annualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance committeeshtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm roche annual report corporate governance committees except presidium chaired nternal audit independent directors g roup audit reports general counsel direct according bylaws board directors board access gives regular briefings audit committee meeting may convened without chairman present ongoing activities audit reports chief request members roche board meets audit risk advisory executive attends audit year assess chairmans performance committee meetings external auditors meeting attended chairman chaired g roup audit independent appraisal function one vicechairmen evaluates reviews groups activities service part management information system board management annual audit plan yearly defined directors informed important issues sales focus areas eg emerging markets thirdparty manage performance etc monthly basis board access ment validated senior management presented electronic information platform provides timely audit committee roche group committed information board directors boards com maintaining high standard internal control throughout mittees system controls set forth worldwide operations management responsible board directors established system controls assessing business risks aspects operation continuously monitored audit committee implementing effective efficient processes corporate governance sustainability committee controls whilst ensuring compliance internal consists following elements external rules regulations report operating financial risks risk management b conducting operational audits group audit deter system mines managements response risks surrounding r oche system place identify manage business processes systems evaluates type risks potentially affecting business roches appropriateness completeness efficiency pro risk management charter sets approach cesses controls action plans implement necessary accompanying responsibilities pharmaceuticals changes enhancements developed together diagnostics divisions global functions conduct businessauditee tracked completion mal risk assessment process least year must statutory auditors see develop risk plans material risks chief compliance officer compliance officers monitored deviations reviewed regular perfor subsidiaries see mance dialogues consolidated group risk report safety health environmental protection depart including target risk profile discussed corporate ment executive committee approved together corporate sustainability committee group business plan also presented audit science ethics advisory group seag issues committee process subject regular reviews relating genetics genetic engineering established findings presented audit committee full board members corporate executive committee f details risk management including risk factors invited attend meetings board directors risk management charter see risk management report person agenda items concerning compliance website financial risk management situation warrants members enlarged specifically described finance report corporate executive committee may also invited system internal controls financial reporting see attend board committees invite chairman pages finance report board corporate executive committee members deliver reports committee meetings may elect commission independent expert reports call services consult ants httpwwwrochecomcorporateresponsibilitybusinessethics riskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm additional information provided finance report note httpwwwrochecomcorporateresponsibilityhtm roche group consolidated financial statements risk management httpwwwrochecomresearchanddevelopment whowearehowweworkethicsinrdethicalconflictshtm corporate governance roche annual report board board committees attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meetings f b humer hoffmann p baschera j bell p bulcke w burns ch franz julius levinson schwan oeri p r voser b weder di mauro member committee invited guest board committee meetings year several blackout periods imposed corporate governance sustainability committee senior employees prohibited trading three meetings approx hours company stock following blackout periods effect composition boards committees remained december january unchanged since march exception mem april april bers board directors retired june july board directors regularly conducts assessment october october performance blackout periods changed chairman members corporate executive committee board directors circumstances warrant maximum ordinary notice period twelve months board directors met six meetings generally management contracts fall within hours length addition scope subsection annex six directive fullday meeting threeday visit major information relating corporate governance subsidiary board committees met follows presidium board directorsnomination commit remuneration shareholdings loans tee two meetings approx hours details regarding remuneration shareholdings loans remuneration committee three meetings approx set forth separate remuneration report pages hours finance report notes audit committee four meetings approx hours roche group consolidated financial statements equity attributable roche shareholders related parties pages listed notes financial statements roche holding ltd board exec u tive remuneration board executive shareholdings pages figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activities remuneration committee members recuse deliberations decisions matters affect interests roche annual report corporate governance participatory rights shareholders statutory auditors participated four meetings audit participatory rights shareholders defined committee roches articles incorporation roche shares issued bearer restrictions admission reports statutory auditor consolidated finan annual general meetings exception shares cial statements financial statements must deposited within specified period date found pages respectively years meeting admittance card must issued finance report shareholders name provided articles incorporation shareholder elect represented kpmg received following remuneration services third party annual general meeting articles statutory auditors roche holding ltd audi incorporation contain restrictions exercise voting tors roche companies including chugai rights quorum requirements stipu lated conformity swiss code obligations articles incorporation shareholders millions chf representing shares nominal value least million auditing services swiss francs request placement items auditrelated services agenda annual general meeting must done accounting services later days date meeting assurance services tax consultancy services change control defensive measures total articles incorporation contain provisions mandatory bid rule swiss law applies statutory auditors elected year annual changeofcontrol clauses components general meeting remuneration based roche nes would terminated event acquisition vesting period restrictions recent years bdo ag served independent proxy preexisting awards would removed paid services according expendi options could exercised immediately ture totalling swiss francs annual general meeting march board directors proposes relationship statutory auditors election bdo ag independent proxy independent proxy period conclusion ordinary annual general meeting roche holding ltd annual general meeting shareholders march shareholders voted appoint kpmg ag kpmg statutory auditors based existing legal information policy requirements swiss code obligations article provided articles incorporation corpo concerning maximum term office seven years rate notices published swiss official gazette auditor charge ian starkey replaced predecessor john commerce daily newspapers designated morris auditorincharge starting business year board directors basler zeitung finanz und wirtschaft information long auditors auditorin lagefi le temps neue zrcher zeitung charge serving capacities provided roche reports halfyear fullyear results business statutory auditors participate audit commit reports published print online formats media tee meetings prepare written oral reports events addition detailed first thirdquarter sales results audits audit committee oversees figures published year april october assesses auditors makes recommendations current list publication dates available english board information authorities responsibilities german internet audit committee see article bylaws httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm httpwwwrochecommediahtm corporate governance roche annual report relevant information documents including media addition roche established business ethics releases investor updates presentations analyst incident reporting beir system enables chief investor conferences available internet compliance officer capture track monitor alleged publications ordered email fax tele violations initial reports local compliance officers phone baselwebmasterrochecom resolution business ethics incidents tel recorded system local compliance officer fax receives specific concrete information material contact address investor relations f hoff alleged violation roche group code conduct mannla roche ltd investor relations group finance one certain predefined categories corporate basel switzerland governance sustainability committee audit tel committee board directors informed fax substantial violations additional information including details specific contact chief compliance officer reports general persons available internet counsel also submits regular reports corporate governance sustainability committee audit c hief compliance officer committee board directors compliance officers network chief compliance officer compliance officers nonapplicabilitynegative disclosure network committed ensuring roche group expressly noted information contained code conduct consistently complied mentioned herein either nonapplicable omission roche group also serves contact person construed negative declaration provided shareholders employees customers suppliers six swiss exchange corporate governance directive general public issues relating implementation commentary thereto compliance code employees parties become aware violations roche group code conduct bring attention managers supervisors report chief com pliance officer urs jaisli direct phone number email ursjaislirochecom disclosures treated confidentially addition end employees may anonymously report irregularities complaints mother tongue via speakup hotline starting december new compliance tool group level called roche group code conduct help advice line introduced strives provide guidance case questions uncertainties interpretation roche group code conduct reference documents furthermore serve p latform ideas suggestions concerning documents httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibilitybusinessethics codeofconducthtm riskmanagementandcompliancehtm roche annual report corporate governance corporate governance roche annual report remuneration report remuneration report principles remuneration committee tracks market data salaries roches success depends abilities dedication leading global pharmaceuticals companies reports entire people recognition forms basis perfor findings full board external consulting firm tow manceoriented remuneration policy system ers watson assists roche performing market comparisons information remuneration committees remit powers roche strive create innovative products benefit procedures making remuneration decisions patients requires outstanding performance found bylaws roche board directors employees takes continuous innovation help patients also outlined sections principles governing sustain revenues create longterm value innovation specific remuneration components en ables us pay competitive compensation employ ees distribute rising dividends shareholders dividend increase th year row one summary main activities outlook primary aims remuneration policy thus encourage following key developments decisions longterm focus align managements interests roche shares rose swiss francs swiss interests roches shareholders holders roches francs past year nonvoting equity securities nonvoting equity securities nes swiss francs swiss francs roches market value rose line billion swiss francs year remuneration committee roches board billion swiss francs billion swiss francs directors meets least twice decides remuneration board members members groups corporate market value achieved end makes roche executive committee base pay bonuses stocksettled stock time worlds ninth largest europes valuable appreciation rights ssars restricted stock units rsus enterprise policy decisions pension benefits terms perfor dividends rose every year steadily past years mance share plan psp awards decided annually dividend billion swiss francs distributed board directors acting upon recommendations remuneration committee past three years proven decisive performance share plan price nonvoting equity starting total aggregate amounts based securities increased value shares decisions submitted general meeting led billion swiss francs rise price approval implementing ordinance excessive com company billion swiss francs billion pensation listed corporations verordnung gegen ber swiss francs represents increase mssige vergtungen bei brsenkotierten aktiengesellschaf remuneration committee assisted consultancy ten vegv general meeting shall vote annually towers watson regularly tracked base pay roche binding effect approval remuneration directors market data directors pay lead board directors resolved board directors ing global pharmaceuticals companies major corporate executive committee details see swiss companies base remuneration roche direc tors remained unchanged years remains unchanged peer set abbott laboratories abbvie amgen astellas astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofiaventis takeda httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm abb credit suisse holcim nestl swiss ubs zurich insurance group actelion nobel biocare sonova straumann synthes roche annual report remuneration report base salaries fixed paid corporate executive com details please refer following sections mittee cec members remained unchanged remuneration report bonus variable paid cec members financial year consist entirely cash payments except case ceo severin schwan reflecting sales remuneration policy growth strong growth earnings per share non roche regularly reviews policy principles remuner voting equity security development pipeline ation part framework employee policies aimed stocksettled stock appreciation rights ssars vari motivating retaining current employees attracting tal able ssars granted cec members vest ented new ones helping roche employees perform together three years exercised consistently high levels remuneration policy designed within seven years grant date unexercised ssars foster value creation reinforce culture performance lapse without compensation since fair value innovation applies nonmanagerial employees ssars calculated grant date using tri managers nomial model american options details see ssars rsus psp remuneration components restricted stock units rsus rights receive intended align managements interests share nonvoting equity securities three year vesting period holders holders nonvoting equity securities give plus value adjustment amount equivalent participating managers additional incentive achieve con sum dividend paid vesting period attribut tinued value growth form longterm total shareholder able number nonvoting equity securities returns creating value roche investors management individual award granted introduced benefits well added value created investors new remuneration component partially replacing ssars management penalised receiving less options value ssar awards reduced balance awarded form rsus key principles underpinning policy company incurs additional costs result focus value creation change aim strengthen alignment pay performance managements interests interests roches share enabling employees share companys success holders groups longterm success fairness transparency remuneration decisions performance share plan psp awards variable psp balanced mix long shortterm remuneration com cycle targeted nes awarded ponents case psp psp psp market competitiveness psp cycles pay award targeted nes plans key performance metric total shareholder return tsr calculated threemonth moving average constant chf exchange rates remuneration committee decided chief executive officer ceo cec members must acquire roche shares andor nes equivalent two annual base salaries ceo one annual base salary cec members respectively end retain holdings long serve cec addition applicable statutory provisions roches long term incentive plans include option partially reclaim distributed compensation result special circum stances clawback details see see also finance report note roche group consoli dated financial statements related parties notes financial statements roche holding ltd board executive remuneration board executive shareholdings pages remuneration report roche annual report remuneration components b bonuses base pay bonuses blocked nonvoting equity securities bonuses awarded individual contributions value cre nes awards stocksettled stock appreciation rights ation meant incentive strive outstanding ssars restricted stock units rsus performance results create new business opportunities bonus share plan psp support fundamental aims roches amounts linked group divisional profits sales remuneration policy remuneration components growth operating profit capital charge opac earn linked companys financial performance commercial ings per share nes growth pipeline achieve success thus align interests roche employees ment measurable qualitative individual functional shareholders performance objectives competitive reasons roche disclose individual performance objectives members explaining principles govern various remu corporate executive committee neration components report details amounts paid member board directors components january following reporting year remuneration com chairman boards remuneration amount mittee decides bonuses payable chairman remuneration component paid member corpo board members corporate executive commit rate executive committee financial year tee respect current reporting year based perfor mance aforementioned objectives annual report submitted approval time remuneration committee also decides form ordinary annual general meeting bonuses awarded cash payments andor blocked nonvoting equity securities andor blocked shares starting board directors shall submit separately general meeting binding approval total aggre c stocksettled stock appreciation rights ssars gate bonuses chairman board directors stocksettled stock appreciation rights ssars plan corporate executive committee retrospectively introduced january establishing uniform system financial year remuneration throughout roche ssars entitle holders benefit financially increase value roches maximum amounts total aggregate remuneration nonvoting equity securities grant date excluding bonuses board directors cor exercise date porate execu tive committee period ordi nary general meeting ordinary general meeting ssar awards allocated individually remuneration tabled first time general committees discretion meetings prospectively binding approval see b restricted stock units rsus base pay starting beginning restricted stock units base pay cash payment determined position rsus rights receive nonvoting equity securities based salary market data leading global pharma three year vesting period plus value adjustment ceuticals companies see footnote reflects individuals amount equivalent sum dividend paid abilities experience performance time pay increases vesting period attributable number nonvoting equity likewise linked individual performance take securities individual award granted account prevailing market conditions see footnote introduced new remuneration component partially companys overall financial situation replacing ssars value ssar awards reduced balance awarded form rsus remuneration committee makes reviews final decision individual base pay paid chairman rsu awards allocated individually remuneration board directors members corporate executive committees discretion vested recipient committee remuneration members three years thereafter resulting nonvoting equity secu board rities may remain blocked ten years roche annual report remuneration reporte performance share plan three overlapping performance cycles psp members corporate executive committee psp psp psp members senior management currently individu closed december als worldwide participate performance share plan psp established periods three years payment performance share plan determined based threeyear comparison total share board directors annual basis acting upon recom holder return tsr peer companies see footnote mendations remuneration committee f ratio corporate executive committee variable remuneration elements bonuses ssarsrsus psp relative fixed base pay criteria bonus ssarsrsus psp individual target value assessed max ssars consideration performance rsus based annual base pay competitors measured january macroeconomic development first year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development blocked nes determined performance determined performance plus value adjustment starting psp dividends nes cycle plus value adjustment grant dividends nes grant performance criteria group objectives group individual contributions group performance divisional business upon remuneration tsr relation performance individual committees decision tsr performance objectives considering profit discretion peer set sales growth opac operating profit capital charge earnings per share nes growth pipeline split group objectives na b individual objectives na remuneration report roche annual report remuneration board directors pursuant switzerlands new ordinance excessive corporate executive committee compensations listed corporations verordnung gegen ber mssige vergtungen bei brsenkotierten aktiengesellschaften resolution vegv roche committed obtaining separate year remuneration committee roches board binding shareholder approvals total remuneration paid directors decides remuneration board members board directors corporate executive com members roches corporate executive committee base mittee described starting agm pay bonuses ssars rsus policy decisions pension amendment roches articles incorporation effect benefits terms performance share plan decided put vote ordinary agm annually board directors acting upon recommenda tions remuneration committee remuneration retrospective approval committee tracks market data salaries leading total aggregate bonus amounts corporate executive global pharmaceuticals companies see footnote reports committee chairman board directors findings full board information committees financial year ended submitted retrospectively remit powers procedures making remuneration deci ordinary agm separate binding approval sions found bylaws roche board direc tors articles incorporation approval changes b prospective approval general meeting march also board executive aggregate remuneration cov lined preceding sections report principles ered vegv submitted prospectively board governing specific remuneration components directors separate binding approval period two ordinary agms bonuses salaries chairman board directors members corporate executive committee following pages provide detailed information remu decided remuneration committee taking neration paid member board directors account revisions roches remuneration policy market member corporate executive committee comparisons leading pharmaceuticals companies financial year include comparisons remuner management changes ation paid previous years remuneration vicechairman board remuneration members board directors board members consists fixed cash payments set members board directors received discretion remuneration committee fixed remuneration cash payments shown remuner remuneration committee assisted consultancy towers ation members board directors table watson tracked cash payments roche directors board activities basic remuneration board market data directors pay leading global directors remained unchanged since remuner pharmaceuticals companies major swiss compa ation members board directors remain nies see footnote unchanged b policy procedure submitting total board exception severin schwan members board executive remuneration shareholder approval directors awarded shares nonvoting equity annual general meeting securities stocksettled stock appreciation rights ssars year annual general meeting agm shareholders rsus approve total remuneration decided board direc tors remuneration committee board directors william burns received honoraria amounting total corporate executive committee us dollars swiss francs serving mem ber board directors chugai pharmaceutical co ltd arthur levinson received payments consulting work serving board genentech amounting us dollars swiss francs httpwwwrochecomaboutrochecorporategovernance list members positions committee memberships articleofincorporationhtm chairmanships see roche annual report remuneration reporta remuneration members board directors additional additional c ompensation additional c ompensation additional special special remuneration committee c ompensation remuneration committee c ompensation memberschairs memberschairs chf chf chf chf chf chf f b humer see b highest total remuneration paid member see b highest total remuneration paid member board directors board directors hoffmann p baschera j bell p bulcke w burns see ch franz julius levinson see oeri schwan see highest total remuneration paid member corporate executive committee remuneration received primary function ceo reflected total remuneration corporate executive committee p r voser b weder di mauro remuneration members board directors retired b gehrig l j r de vink total exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration serving vicechairman board period january march prorated remuneration period january march b highest total remuneration paid member programmes psp rsus longer enrolled board directors roche ssars programme chairman franz b humer member board highest total remuneration chairmans severin schwan executive member board directors remuneration consists base salary bonus awards received remuneration primary function ceo chairman board since handover executive reflected highest total remuneration paid member function ceo annual general meeting march corporate executive committee included total receive additional ssars nes amount paid corporate executive committee remuneration report roche annual report highest total remuneration paid member board directors chf chf chf salary bonus cash paymentblocked shares proposal ordinary agm total pension fundsmgb roche connect total value shares transfer end april calculation value based three months average price swiss francs october december consideration reduction value due blocking period years reduced market value detailed calculation remuneration see annual report mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes annual expense allowance chf payments tax consulting services chf including employer contribution ahvivalv chf c stocksettled stock appreciation rights ssars e board remuneration subject approval december william burns mem annual general meeting ber board directors holding ssars due former position members corporate executive com submission chairmans total aggregate bonus mittee held stocksettled stock appreciation rights ssars binding vote annual general meeting shown ssars table board directors proposes awarding chairman board bonus roche shares blocked period total remuneration paid board directors ten years valued swiss francs respect members board directors received financial year submit proposal remuneration totalling swiss francs ordinary annual general meeting agm binding vote swiss francs anticipation enactment switzerlands new ordinance excessive compensation listed corporations ver loans credits granted members ordnung gegen bermssige vergtungen bei brsenko board directors tierten aktiengesellschaften vegv horst teltschik former member board chairman board receive additional bonus directors received honoraria amounting euros respect financial year payable april swiss francs serving boards several roche remuneration committee adopt bonus proposal late subsidiaries germany euros ie swiss submit proposal shareholder approval francs horst teltschik decided stand ordinary agm reelection board member b submission boards total aggregate future additional remuneration paid remuneration binding shareholder vote board directors proposes ordinary agm approve board remuneration totalling swiss francs period ending ordi nary agm ordinary agm ordinary agm rounded sum swiss francs excluding bonuses amount includes annual salary swiss francs new chairman board roche annual report remuneration reportin franz b humer chairman board direc remuneration members corporate executive tors receive remuneration swiss francs committee general provisions assigning authority cash work end march prorated decisions corporate executive committee remuneration paid ordinary agm therefore remuneration committee board directors included boards aggregate future remuneration outlined pages remuneration report thereafter former chairman board directors severin schwan executive member board directors franz b humer serve five years advisory capacity received remuneration primary function ceo presidium phase handover reflected highest total remuneration paid member mandate intensive afterwards reduced corporate executive committee see considerably total remuneration set board cluded total amount paid corporate executive directors published roches annual report said committee see h remuneration maximum swiss francs total included figure given future total remuneration board directors subject shareholder approval paid ordinary gen eral meeting highest total remuneration paid severin schwan member corporate executive committee highest total remuneration paid member corporate executive committee chf chf chf salary ssars grant value according trinomial model american call options rsus restricted stock units pension fundsmgb insurances roche connect subtotal bonus cash payment blocked nonvoting equity securitiesshares psp total value calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value detailed calculation remuneration see annual report number ssars grant value according trinomial model american call options chf trinomial model american call options value described remuneration members corporate executive committee c stocksettled stock appreciation rights ssars number rsus grant value chf nes average market price days period prior grant date march per rsu calculation value consideration reduction value due additional blocking period years reduced market value mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits shares transfer april calculation value based three months average price swiss francs october december consideration reduction value due blocking period years reduced market value total estimated value psp award originally targeted nes awarded nes total spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per non voting equity security nes based number nes originally targeted nes nes respectively subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved includes annual expense allowance chf payments tax consulting services chf excluding employer contribution ahvivalv payments chf remuneration report roche annual report remuneration remaining members corporate executive committee base pay chf annual salary annual salary annual salary ayyoubi r diggelmann hippe g keller oday total member corporate executive committee prorated remuneration period april december including chf loss pension rights granted former employer contractual agreement b bonus except severin schwan members corporate remuneration committee board directors deter executive committee receive bonus mined corporate executive committee members bonuses cash payment due end april severin january based performance schwan receive bonus form roche shares agreed objectives total aggregate amount bonuses blocked ten years bonus payment due brought forward binding vote annual general end april see meeting bonus bonus bonus bonus total total total chf chf chf ayyoubi cash payment blocked nonvoting equity securities total bonus r diggelmann cash payment blocked nonvoting equity securities total bonus hippe cash payment blocked nonvoting equity securities total bonus g keller cash payment blocked nonvoting equity securities total bonus oday cash payment blocked nonvoting equity securities total bonus total member corporate executive committee prorated remuneration period april december roche annual report remuneration reportc stocksettled stock appreciation rights ssars time prior maturity called american option com ssars shown ssars table pared european option allows exercise introduced roche january place stock maturity date options ssars entitle holders benefit financially increase value roches nonvoting equity securities numbers ssars strike prices expiry dates nes grant date exercise date grant values ssars shown ssars table strike price ssars terms multiyear plan numbers ssars calculated time closing price roche nes grant date ssars issue entered values table vest three years grant date vested ssars exercised converted nes within seven years grant date unexercised ssars lapse without compensation fair value ssars calculated grant date information trinomial model american options please refer boyle phelim p lattice framework options pricing using trinomial model american options trinomial two state variables journal financial quantitative model effective method valuation american call analysis volume issue mar wwwrochecom trinomialmodelpdf options considers possibility exercising option see strike prices table ssars stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf ayyoubi r diggelmann hippe g keller oday total member corporate executive committee restricted stock units rsus replacing ssars value ssar awards reduced starting beginning restricted stock units balance awarded form rsus rsus rights receive nonvoting equity securities three year vesting period plus value adjustment rsu awards allocated individually remuneration amount equivalent sum dividend paid committees discretion vested recipient vesting period attributable number nonvoting equity three years thereafter resulting nonvoting equity secu securities individual award granted rities may remain blocked ten years introduced new remuneration component partially remuneration report roche annual report restricted stock units rsus rsus rsus number value chf ayyoubi r diggelmann hippe g keller oday total calculation value number rsus multiplied grant value chf nes average market price days period prior grant date march per rsu calculation value consideration reduction value due additional blocking period years reduced market value e performance share plan psp securities market prices dividend yields ie total members corporate executive committee shareholder return tsr calculated chf con members senior management currently individu stant exchange rates reduce effect shortterm mar als worldwide participate performance share plan ket fluctuations security prices averaged three psp months october december prior start perfor mance cycle three months october decem psp moved overlapping threeyear performance ber end cycle cycles new cycle beginning year thus three cycles progress psp psp roche securities perform better average peer psp whereas psp closed set roches tsr increases least cycle december targeted nes awarded board directors elect increase nes award maximum award double original level reserved target previous years psp psp psp number nes according psp plan starting psp psp closed without awards cycle plus value adjustment amount targeted nes equivalent sum dividend paid vesting period attributable number nonvoting equity securi provisions plan number nonvoting ties individual award granted equity securities nes reserved partici requires roche securities perform well better pants cycle number securities actually awarded peer set event investment depend whether extent investment roche securities underperforms average return delivered roche securities shares nes outperforms average peer companies fewer nes awarded return investment securities issued peer set comparator companies comparisons based see footnote roche annual report remuneration reportperformance share plan psp total estimated awards value psp awards targeted nes nes nes number awarded awarded awarded target number target number nes nes psp nes psp psp psp psp psp value chf value chf value chf value chf ayyoubi r diggelmann hippe g keller oday total member corporate executive committee total estimated value psp award originally targeted nes awarded spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved nes reserved plan members f indirect benefits corporate executive committee shown table employer contributions made social security board directors decide schemes pension plans groupwide employee stock actual level nes cash equivalent awards cycles purchase plan roche connect respect members close corporate executive committee shown indirect financial years respectively aim psp provide benefits table pages incentive participants achieve steady value growth roche connect voluntary stock purchase plan offering end psp cycle based three employees opportunity buy roche nonvoting equity month moving average distributed dividends totalling securities nes amount equal annual billion swiss francs billion swiss francs salary discount nes purchased plan billion swiss francs billion swiss subject holding period four years switzerland francs tsr roche securities nes shares ranked th compared peer set companies operating industry therefore according terms plan participants received originally targeted nes see table details remuneration report roche annual report indirect benefits pension payments pension payments funds tax funds tax mgb ahviv roche consulting mgb ahviv roche consulting insurances alv connect services insurances alv connect services chf chf chf chf chf chf chf chf ayyoubi r diggelmann hippe g keller oday total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits g remuneration emoluments loans executive remuneration subject approval members corporate executive committee additionally annual general meeting receive annual expense allowances swiss francs totalling swiss francs ubmission executive total aggregate bonuses binding vote annual general meeting based contractual obligations roche paid indi board directors proposes awarding members vidual members corporate executive committee corporate executive committee bonuses totalling childrens schooling costs foreign tax obligation relo swiss francs respect financial year cation costs totalling swiss francs swiss francs submit proposed total amount ordinary annual general meeting agm loans credits granted members binding vote anticipation enactment switzer corporate executive committee lands new ordinance excessive compensation listed corporations verordnung gegen bermssige ver pensions totalling swiss francs paid gtungen bei brsenkotierten aktiengesellschaften vegv former corporate executive committee members b ubmission executive total aggregate maximum regular period notice members remuneration binding shareholder vote corporate executive committee months board directors proposes ordinary agm changeofcontrol clauses employment contracts approve remuneration corporate executive committee totalling swiss francs ordinary h total remuneration paid members agm ordinary agm rounded sum swiss corporate executive committee francs excluding bonuses period ending members corporate executive committee ordinary agm received remuneration totalling swiss francs swiss francs including ahvivalv amount composed base pay longterm incentives ssars rsus calculated grant value without consid additional remuneration mentioned ering reductions value due blocking periods applica payments paid current former members cor ble psp calculated time reservation nonvot porate executive committee ing equity securities taking account potential double well contributions pension benefits roche annual report remuneration report alignment interests managers pensation according ssars plan rules serious mis shareholdersholders nonvoting equity securities conduct participant may include inter alia ssars psp remuneration components intended activity leading serious disciplinary action align managements interest shareholders repeated willful failure perform duties holders nonvoting equity securities give participat reasonably assigned roche ing managers additional incentive achieve continued violation law public regulation value growth form longterm total shareholder returns commission crime creating value roche investors management benefits gross negligence willful misconduct employment well added value created investors manage engaging conduct bringing disgrace disrepute roche ment penalised receiving less andor subsidiaries violation roches directives guidelines relating business conduct clawback addition applicable statutory provisions roches long according regulations psp programme origi term incentive plans include option partially reclaim dis nally targeted awarded nes shall lapse without tributed compensation result special circumstances compensation upon notice termination employment clawback given reason redundancy disability retire ment employee voluntarily serves notice termination employment ssars rsus unvested date termination employment lapse immediately without guidelines security holdings compensation board directors decided ceo cec members must acquire shares andor nes equivalent upon termination employment result serious miscon two annual base salaries ceo one annual base salary duct ssars rsus granted outstanding whether respectively end retain holdings vested unvested shall lapse immediately without com long serve cec type security value ceo shares andor nes x annual base salary members corporate executive committee shares andor nes x annual base salary security holdings note financial statements roche holding ltd directors andr hoffmann andreas oeri members significant shareholders addition founders families closely associated december december respectively belong shareholder group pooled voting rights members board directors persons closely asso end group held shares ciated members cec persons issued shares detailed information group closely associated held shares nes shown found finance report note roche group con table security holdings solidated financial statements related parties remuneration report roche annual report security holdings december december close close relatives relatives security security holdings holdings shares nes number others shares nes number others number number type number number number type number board directors f b humer ssars see hoffmann ubs longshort certificates linked roche bearer shares roche nonvoting equity securities valor isin ch expiry date march p baschera j bell p bulcke w burns ssars ssars see see ch franz julius levinson oeri ubs longshort certificates linked roche bearer shares roche nonvoting equity securities valor isin ch expiry date march schwan see security holdings na na na na corporate executive committee p r voser b weder di mauro retired direc tors board b gehrig na na na na l j r de vink na na na na american depository receipts adr rhhby us isin us total roche annual report remuneration reportsecurity holdings december december close close relatives relatives security security holdings holdings shares nes number others shares nes number others number number type number number number type number corporate executive committee schwan ssars see ssars see ayyoubi ssars see ssars see r diggelmann ssarsoptions ssarsoptions see see hippe ssars see ssars see g keller ssars see ssars see shares shares oday ssars see ssars see total shares shares shares held shareholder group pooled voting rights listed remuneration report roche annual report ssars number ssars held current former members corporate executive committee december total corporate executive committee schwan ayyoubi r diggelmann hippe g keller oday total former corporate executive committee members w burns none none none none strike price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options values according corresponding annual reports former position options held options shown table issued roche employee stock options option entitles holder purchase one roche nonvoting equity security nes terms multiyear option plan strike price options shown closing price roche nes grant date options shown nontradable onethird options subject vesting period one year onethird vesting period two years onethird vesting period three years unvested options lapse without compensation employment terminated voluntarily reasons retirement vested options must exercised within limited period time william burns receive additional ssars william burns received ssars member corporate executive committee roche annual report remuneration report remuneration report roche annual report web research development roches pharmaceuticals diagnostics pipelines wwwrochecompipeline personalised healthcare wwwrochecompersonalisedhealthcare group policies positions guidelines wwwrochecomresponsibilitysustainabilitypositionspoliciesdownloadshtmguidelines clinical trials safety wwwrochecomclinicaltrials wwwrochecommanagingmedicationsafety global standards httpwwwrochecomresearchanddevelopmentwhowearehowweworkclinicaltrialsglobalstandardshtm animal welfare wwwrochecomanimalwelfare manufacturing procurement pharmaceutical supply chain initiative wwwpharmaceuticalsupplychainorg stakeholder engagement wwwrochecomstakeholderengagement supplier code conduct wwwrochecomrochesuppliercodeofconductpdf markets products wwwrochecomproducts access healthcare overview wwwrochecomaccesstohealthcare genentech access solutions wwwgenentechaccesssolutionscom list patient groups supported wwwrochecompatientgroups integrity responsible marketing wwwrochecombusinessintegrityandresponsiblemarketing roches policies guidelines positions wwwrochecompositionspoliciesdownloadshtm responsible business roche group code conduct wwwrochecomcodeofconduct roche supplier code conduct wwwrochecomrochesuppliercodeofconductpdf positions policies guidelines wwwrochecompositionspoliciesdownloadshtm roche position respecting human rights wwwrochecomresponsibilityemployeeshumanrightshtm risk management compliance wwwrochecomriskmanagementandcompliance integrity responsible marketing wwwrochecombusinessintegrityandresponsiblemarketing list patient groups supported wwwrochecompatientgroups roche clinical trials patient safety wwwrochecomclinicaltrials wwwrochecommanagingmedicationsafety counterfeiting wwwrochecomcounterfeiting patents intellectual property wwwrochecompatents stakeholder engagement wwwrochecomstakeholderengagement roche annual report additional online informationour people employees wwwrochecomemployees global careers portal httpcareersrochecom employment policy wwwrochecomemploymentpolicypdf group policies positions guidelines wwwrochecompositionspoliciesdownloadshtm commitments wwwrochecomcommitments health safety wwwrochecomenvironment community involvement roche commissions httpwwwrochecomrochecommissionshtm roche continents httpwwwrochecontinentsnetrochecontinentshtml roche childrens walk httpwwwrochecomchildrenswalkhtm safety security health environment environmental protection wwwrochecomenvironment policies guidelines position papers httpwwwrochecomresponsibilityenvironmentourshepoliciesguidelinesandpositionpapershtm goals performance httpwwwrochecomresponsibilityenvironmentourshegoalsandperformancehtm corporate governance remuneration report httpwwwrochecomaboutrochecorporategovernancehtm httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm httpwwwrochecomaboutrochemanagementboardofdirectorshtm httpwwwrochecomaboutrochemanagementexecutivecommitteehtm httpwwwrochecomaboutrochecorporategovernanceannualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernancecommitteeshtm httpwwwrochecomcorporateresponsibilitybusinessethicsriskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm httpwwwrochecomcorporateresponsibilityhtm httpwwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm httpwwwrochecommediahtm httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernancecodeofconducthtm wwwrochecomtrinomialmodelpdf additional online information roche annual report independent assurance report roche corporate responsibility reporting corporate governance sustainability committee defined guidelines people donations roche holding ag basel roche sponsorships key figures internally gathered collated aggregated engaged perform assurance procedures principles summarised pages report provide limited assurance aspects corporate define scope reporting responsibility cr reporting roche included annual report report accuracy completeness cr indicators subject inherent limitations given nature methods scope subject matter determining calculating estimating data limited assurance engagement focused following surance report therefore read connection data information disclosed cr reporting roche roches internal guidelines definitions procedures consolidated subsidiaries year ended decem reporting cr performance ber management reporting processes respect responsibility methodology cr reporting material aspects preparation roche corporate governance sustainability commit safety security health environmental protection tee responsible subject matter criteria people donations sponsorships key figures well well selection preparation presentation related control environment relation data aggre selected information accordance criteria gation key figures responsibility form independent opinion based key figures including scope greenhouse gas limited assurance procedures whether anything come emissions business travel tables graphs attention indicate identified cr information pages people key figures disclosed pages selected contained report stated mate report rial respects accordance reporting criteria consolidated data information roche group level relation donations sponsorships breakdown planned performed procedures accordance disclosed international standard assurance engagements isae assurance engagements audits criteria reviews historical financial information standard management reporting processes respect cr requires comply ethical requirements plan reporting key figures assessed internal perform assurance engagement obtain limited assur policies procedures set forth following ance identified cr information roche group internal cr reporting guidelines based responsible care health safety environmental subject matter provide limited assurance protection reporting guidelines published european nature timing extent procedures gathering suf chemical industry council cefic sustainability ficient appropriate evidence deliberately limited relative reporting guidelines g published global reasonable assurance engagement reporting initiative gri roche group internal corporate reporting manual ver complied independence ethical sion sustainability reporting economic performance requirements code ethics professional accoun data tants issued international ethics standards board roche annual report independent assurance report roche corporate responsibility reportingaccountants founded fundamental principles carried work data reported prior integrity objectivity professional competence due care reporting periods performed work respect confidentiality professional behaviour projections targets conducted work data outlined subject matter defined performed tasks services roche would conflict independence believe evidence obtained sufficient responsible preparation part report appropriate provide basis assurance conclu therefore qualify independent defined code sions ethics applicable legal regulatory requirements limited assurance conclusion summary work performed based work described report assurance procedures included amongst others fol nothing come attention causing us believe lowing work roche group internal cr reporting guidelines based evaluation application gri g sustainability reporting guidelines well roche group guidelines cefic guidelines applied material respects reviewing application roche group internal cor nothing come attention causing us believe porate cr donations sponsorships guidelines internal reporting processes collect aggregate site visits management inquiry people donations sponsorships data visiting selected sites roches pharmaceuticals functioning designed provide appropriate basis diagnostics divisions argentina belgium nether disclosure material respects lands south korea taiwan selection based nothing come attention causes us believe quantitative qualitative criteria cr information mentioned subject matter interviewing personnel responsible internal cr reporting disclosed within cr reporting roche annual data collection sites visited roche report stated material respects accor group level determine understanding application dance reporting criteria roches internal cr guidelines assessment key figures performing tests sample basis evidence supporting zurich january selected people donations sponsorships key fig ures roche accident rate energy consumption green pricewaterhousecoopers ag house gas emissions related energy consumption halo genated hydrocarbons waste headcountfte data staff statistics labor practices information contributions philanthropic organizations patient organisations health institutions public policy bodies concerning completeness christophe bourgoin stephan hirschi accuracy adequacy consistency inspection documentation analysis relevant policies principles inspecting relevant documentation sample basis cluding roche group cr policies management reporting structures documentation inspecting principles roche materiality process providing definition development adherence gris social environmental reporting requirements assessment processes data consolidation reviewing management ofand cr reporting processes people donations sponsorships key figures assessing consolidation process data roche group level independent assurance report roche corporate responsibility reporting roche annual report published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking statements tel forwardlooking statements may identified words believes expects anticipates projects intends seeks fax estimates future similar expressions discussion among things strategy goals plans intentions various factors may media office cause actual results differ materially future group communications reflected forwardlooking statements contained annual basel switzerland report among others pricing product nitiatives com tel petitors legislative regulatory developments economic fax conditions delay inability obtaining regulatory approvals bringing products market fluctuations currency exchange rates g eneral financial market conditions uncertainties investor relations discovery development marketing new products new uses basel switzerland existing products including without limitation negative results tel clini cal trials research projects unexpected side effects pipeline fax marketed products increased government pricing pressures interruptions production loss inability obtain ade website quate protection intellectual property rights litigation loss wwwrochecom key executives employees adverse publicity news coverage corporate sustainability committee statement regarding earnings per share growth profit tel forecast interpreted mean roches earnings email corporatesustainabilityrochecom earnings per share subsequent period neces sarily match exceed h istorical published earnings earnings order publications per share roche tel fax trademarks mentioned enjoy legal protection email baselwebmasterrochecom links thirdparty pages provided convenience express opinion content thirdparty pages next annual general meeting expressly disclaim liability thirdparty information march use roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communicationsf hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche annual report x key figures group sales operating free cash flow millions chf cer millions chf cer core operating profit ifrs net income millions chf cer millions chf cer core earnings per share dividend annual report xxx x chf cer chf total shareholder return value chf invested period ending dec feb apr jun aug oct dec roche gs price roche b price peer set index sustainable company patients clinical trials patients treated employees global leader innovation biotech oncology vitro diagnostics hospital markets cer constant exchange rates average fullyear prices translated constant chf exchange rates ifrs international financial reporting standards usd eur jpy gbp proposed board directors one roches top selling products fulltime equivalents rochearugengindd rochearfront coverengindd rochearkey figureseng